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CHAPTER 1 
Introduction 
 
Osteogenesis Imperfecta  
Osteogenesis imperfecta (OI), or “brittle bone disease”, is a genetic disorder of collagen 
characterized by brittle bones [1].   Patients with OI have increased bone fragility and are 
susceptible to fracture from minimal force.  In many cases, skeletal deformities and short stature 
are also observed.  OI fragility symptoms tend to be most prominent in children, although the 
condition often persists throughout life.  The increased bone fragility of OI can be related to 
reductions in tissue quality or tissue amount or both.   
Classically, OI was identified as an autosomal dominant genetic disorder, and these 
account for approximately 90% of the genetic mutations in OI.  More recently, recessive OI 
mutations have been found in proteins that participate in prolyl 3-hydroxylation or those 
responsible for proper folding of the collagen triple helix [2–4].   Collectively, recessive OI only 
accounts for  ~10% of all cases. 
The cause of OI is not singular, but rather arises from hundreds of different genetic 
mutations associated with Type I collagen [5].  As a result of this large number of mutations, 
there is a wide variety of clinical presentation.  For example, some cases of autosomal dominant 
OI are a mild form caused by a deficient COL1A1 allele.  As the other functioning COL1A1 
allele remains in these patients, they can synthesize normal collagen heterotrimers, but do so at a 
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slower  rate[6].  While patients with this mutation do exhibit increased bone fragility, they have 
relatively normal stature and minimal bone deformity.  Conversely, patients with mutations that 
feature an amino acid substitution within either COL1A1 or COL1A2 allele can have a more 
severe phenotype.   Every third amino acid on COL1A1 or COL1A2 allele is a glycine – the 
smallest of the 20 amino acids.  OI mutations are commonly an amino acid substitutions for a 
single glycine residue [7].  The specific amino acid substitution, as well as specific position of 
this substitution along a COL1A1 or COL1A2 allele, influences the phenotype of the specific 
mutation.   Patients with these substitutions can be perinatal lethal.  Alternatively, depending on 
the specific mutation, many survive.  The range of presentation includes wheelchair bound 
patients with progressive limb deformity and extremely high fracture risk, and patients who 
achieve ambulation with moderate fracture risk. 
Before genetic technology allowed researchers the ability to determine the specific 
mutation in an OI patient, they were classified into groups based upon clinical presentation.   
These initial efforts were made by Sillence, and consist of a numerical classification scheme [8].  
Briefly, Type I OI describes those with a single functioning COL1A1 allele and present 
moderately [6].  Type II OI is characterized by perinatal lethality [9].   Of surviving OI types, 
Type III patients have the most severe form, with progressive severe limb deformity and extreme 
fracture risk.  Type IV OI represents a less severe form of OI, and although patients suffer many 
fractures, they are typically able to achieve ambulation.  Additional types exist, but these four 
comprise the bulk of OI cases, and include the specific type of OI studied in this dissertation.  
While efforts to correlate genotype to phenotype have revealed patterns and provided 
mechanistic insight for OI and collagen, clinical presentation and Sillence Type remain the 
standard way to categorize patients and treatment regimens. 
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OI is a highly variable disease, and what is true of a specific case of OI is not 
generalizable to all.  However, several features frequently exist in OI.  Most importantly, patients 
with OI have significantly reduced bone mass, and in many cases, altered bone material 
properties.  At the cellular level, patients frequently have increased osteoclastic bone resorption 
[10, 11].  While greater remodeling also increases bone formation, the inferred bone formation 
per cell in OI is less than normal [11].  The phenotype of OI becomes less severe with time, and 
fracture rates often decrease after puberty [12].  In addition, patients with OI are frequently short 
in stature.  Finally, a recent report in several OI mouse models suggests that elevated TGF-β 
levels may be a common factor in the pathology of OI [13]. 
 
The Brtl/+ Mouse Model of Osteogenesis Imperfecta 
Brtl/+ is a mouse model of moderately severe Type IV OI.  Brtl/+ is heterozygous for a 
glycine to cysteine substitution at the 349
th
 position of one col1a1 allele [14].  The Brtl/+ mouse 
was created to reproduce a mutation found in a child with Type IV OI and as such, reproduces 
many features of the typical OI phenotype.  These include reduced bone mass and strength, 
particularly in young animals – which mimics the phenotypic reduction in OI fracture risk with 
age.   The material properties of Brtl/+ matrix are also altered, and increased brittleness and 
mineralization have been observed [15, 16].  At the cellular level, Brtl/+ has increased osteoclast 
surface with a concomitant reduction, or no change, in bone formation, depending on animal age 
[17].   In culture, Brtl/+ osteoclasts demonstrate increased bone resorption similar to the in vivo 
phenotype [17, 18].   Interestingly, initial cell-matrix exchange experiments suggest that the 
Brtl/+ matrix may cause some of the observed osteoclast differences independent of intrinsic 
differences in Brtl/+ cells [16, 18].  In addition, increased endoplasmic reticulum size due to 
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retention of mutant collagen has been observed in Brtl/+ fibroblasts, and may relate to osteoblast 
differences [19].   In summary, the Brtl/+ mouse is appropriate for studying candidate OI 
treatments in young and adult mice because it recapitulates a clinically observed mutation as well 
as the adaptation of an OI skeleton over time. 
 
Treatments for OI Patients 
Presently, the most common drug therapy for the treatment of pediatric OI are anti-
resorptive bisphosphonates.  The anti-resorptive nature of bisphosphonates is appealing as 
increased bone turnover has been observed in OI [10, 11].  However, the results from controlled 
pediatric OI clinical trials suggest a mixed efficacy in reducing fractures [20–24].  While 
effective at increasing vertebral BMD and sometimes vertebral functional outcomes such as 
vertebral height, an effect on long bone fracture rate is often absent.  Moreover, while 
bisphosphonates are generally well tolerated, there are several concerns about their application in 
a growing skeleton.  These include retention of calcified cartilage, long term retention of 
bisphosphonates in the skeleton, and potential for altered growth dynamics [25–28].  On the 
anabolic side, growth hormone therapy has been shown to increase linear growth rates in some 
pediatric OI patients.  However, in the ~50% patients where growth hormone does not have a 
discernible benefit, it may even exacerbate the OI phenotype by increasing osteoclast surface 
[29].  Parathyroid hormone, while an approved anabolic therapy for osteoporosis, is not available 
for use in pediatric OI patients with an open growth plate due to a risk of osteosarcoma [30].   
In adult OI, bisphosphonates are also used in the clinic despite limited clinical trials.  The 
data suggests bisphosphonates are effective at increasing BMD in the axial skeleton, but fracture 
rate benefits are inconclusive [31–34].  Unlike pediatric OI, anabolic parathyroid hormone is not 
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contraindicated due to risk of osteosarcoma for use in adult OI.  Initial studies investigating 
teriparitide in adults with OI suggest that it is effective in patients with Type I OI, but not in 
Type III and IV [35]. 
More effective therapies are needed for both pediatric and adult OI and no consistently 
effective anabolic therapy has been established in either case. 
 
Sclerostin and Early Use of Sclerostin Inhibiting Antibodies 
Sclerostin is a potent inhibitor of bone formation, named after a mutation in the protein 
was found to cause the long-diagnosed clinical bone overgrowth condition sclerosteosis [36, 37].  
An absence of sclerostin is observed in patients with bone overgrowth in sclerosteosis, 
implicating the protein as an inhibitor of bone formation.  Physiologically, sclerostin is secreted 
by osteocytes and it is currently thought that sclerostin passes through the canalicular network to 
the bone surface [38].   Once at the bone surface, sclerostin is purported to bind LRP4, LRP5 and 
LRP6 on osteoblasts and inhibit canonical Wnt/beta-catenin signaling [38–40].   SOST KO 
murine models recapitulate the skeletal overgrowth condition and have extremely high levels of 
bone formation, without a large increase in bone resorption[41]. 
As sclerostin is a potent inhibitor of bone formation, monoclonal inhibiting antibodies to 
sclerostin (Scl-Ab) have been developed by several pharmaceutical companies, and are presently 
in clinical trials for the treatment of osteoporosis and have demonstrated anabolic efficacy [42, 
43].  Preclinical studies have confirmed the anabolic potential, as well as examined the 
mechanism, in a variety of models.   In a rat ovariectomy model, Scl-Ab was able to increase 
bone mass and strength to levels the same as, or significantly greater than, sham controls [44].  
This was primarily a result of large increases in bone formation rates of ~100% to ~1000%, 
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depending on skeletal site.  A decrease in osteoclast surface was observed, suggesting an 
uncoupling of resorption from formation.  Moreover, detailed histologic study has revealed that 
Scl-Ab primarily increases bone mass by stimulation of modeling based formation [45].  Unique 
from anabolic PTH, where increased remodeling can be blunted by antiresorptive therapy,  
Scl-Ab induced bone gains are not affected by prior, or co-treatment with a bisphosphonate [46]. 
  
Global Hypothesis 
Given the lack of anabolic treatment options for OI outlined above, and the anabolic 
potential of Scl-Ab, this thesis will investigate the following global hypothesis: 
In rapidly growing and adult Brtl/+ models of OI, Scl-Ab will increase bone formation, 
resulting in increased bone mass and strength, without affecting the underlying alteration in 
material property and composition. 
 
Chapter Overview 
 
Chapter 2 of this thesis describes the first report of Scl-Ab in a mouse model of OI [47].  
Specifically, it demonstrates the anabolic efficacy of Scl-Ab using a short-term 2 week treatment 
protocol in an 8 week old Brtl/+ mouse model.  Significant gains in bone formation were 
observed by dynamic histomorphometry, as well as increased serum osteocalcin.  Surprisingly, 
whole bone mass and strength were also improved despite the short-term treatment regimen. 
Chapter 3 investigates the treatment of an adult 6mo old Brtl/+ model of OI with a 5 
week Scl-Ab treatment regimen [48].  Scl-Ab significantly increased femoral trabecular bone 
mass, increased cortical bone formation rate and cortical bone mass, leading to improved bone 
strength.  Unexpectedly, reductions in bone brittleness were also observed with Scl-Ab. 
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As OI is primarily a pediatric disease, and the 8 week old animals studied in Chapter 2 
were not rapidly growing, we pursued studies in a younger Brtl/+ mouse.  In Chapter 4, 3 week 
old Brt/+ mice were treated with Scl-Ab for 5 weeks, at an identical dose as used in Chapter 3.  
During the experiment, body mass doubled, confirming a high growth rate, but treatment had no 
effect on bone length or body mass.  In rapidly growing Brtl/+ mice, Scl-Ab again increased 
bone formation, leading to greater cortical bone mass and strength.  Interestingly, bone 
brittleness was only increased in WT, but not Brtl/+, rapidly growing mice. 
Chapters 3 and 4 represent a set of parallel experiments at two animal ages with identical 
outcomes.  These chapters are best read together as there is additional value gained from 
contrasting the data.    For example, there are different effects of Scl-Ab in Brtl/+ femoral 
trabecular bone depending on animal age.  In addition, an unexpected reduction in bone 
brittleness with Scl-Ab therapy was only observed in adult 6 mo Brtl/+, but not rapidly growing 
animals.  Finally, a detailed regional dynamic histomorphometry analysis was carried out and 
revealed that while Scl-Ab was anabolic at both animal ages, the manner in which it increased 
bone formation on surfaces around the cortex was different in rapidly growing vs adult animals. 
Chapter 5 describes an investigation into the material properties (nanoindentation) and 
composition (raman spectroscopy) of bone formed under the influence of Scl-Ab.   While the 
previous chapters demonstrate that Scl-Ab can increase bone formation and whole bone strength, 
it is not clear whether the treatment has an effect on material composition.  Fluorescent labels 
were used to control for tissue age in all analysis, and both raman spectroscopy and 
nanoindentation outcomes were analyzed at multiple tissue ages.  Data suggest that there 
differences in material composition (carbonate to phosphate and mineral to matrix ratios) as a 
result of Scl-Ab, but no changes were observed in elastic modulus. Moreover, the response was 
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similar between WT and Brtl/+.  Not to be lost in this study is the interesting interaction between 
tissue age and animal age. 
In conclusion, these data collectively suggest that Scl-Ab can stimulate bone formation in 
rapidly growing and adult Brtl/+ model of Type IV OI.  Increased bone formation led to 
increased bone mass and improved long bone strength.  These initial data suggest that Scl-Ab 
may be beneficial for OI patients, with the potential to stimulate bone formation and reduce 
fracture risk.  
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CHAPTER 2 
Short Term Sclerostin Antibody Treatment Improves Skeletal Parameters in a  
Brtl/+ Mouse Model of Osteogenesis Imperfecta 
Introduction 
 Osteogenesis imperfecta (OI), or “brittle bone disease”, is a heritable disorder caused 
predominantly by mutations in type I collagen or in proteins that promote the folding or post-
translational modification of collagen.  Patients with OI have increased bone fragility and are 
susceptible to fracture from minimal force, skeletal deformities and growth deficiency.  OI 
fragility symptoms are generally most prominent in children; the disorder ranges in severity from 
mild forms with slightly elevated fracture risk to perinatal lethality [1].  
Current treatment options for OI focus on anti-resorptive bisphosphonates (BP) which 
have been shown effective at increasing vertebral areal bone mineral density and height in 
clinical trials.  However, BP effects in long bones are less evident and most pediatric OI trials 
observe little or no functional benefit [2–6].  Moreover, while BP therapy has been generally 
well tolerated in pediatric OI patients, there are concerns about long term retention of BPs in the 
skeleton and use in a growing population [7]. 
Sclerostin antibody (Scl-Ab) is a novel anabolic bone therapeutic presently in clinical 
trials for treatment of osteoporosis [8].  Sclerostin is secreted primarily by osteocytes and 
negatively regulates bone formation by binding to the LRP4/5/6 complex, inhibiting anabolic 
canonical wnt signaling in osteoblasts [9–11].  As a result, treatment with a neutralizing Scl-Ab 
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reduces sclerostin inhibition of canonical wnt signaling and is highly anabolic in pre-clinical 
models and in a phase 1 clinical trial of men and postmenopausal women [8, 12, 13].  Whether 
Scl-Ab therapy is capable of stimulating osteoblast activity in cells harboring a typical OI-
causing mutation has yet to be demonstrated.  
The Brtl/+ mouse is a knock-in model for moderately severe Type IV OI with a G349C 
point mutation on col1a1 that recreates an identical defect found in an OI patient [14].  The 
Brtl/+ mouse recapitulates multiple features of the observed clinical phenotype, including 
smaller size, reduced BMD, more severe phenotype at young ages, increased bone brittleness and 
increased bone turnover [15, 16], making it an appropriate model for testing the anabolic efficacy 
of Scl-Ab in OI.  The purpose of this study was to determine whether a short-term intervention 
with Scl-Ab in the Brtl/+ model of OI would be effective at stimulating an anabolic skeletal 
response and improving long bone strength.   
 
Materials and Methods 
Animals 
Wildtype (WT) and Brtl/+ mice are maintained on a mixed background of Sv129/CD-
1/C57BL/6S, and all Brtl/+ animals were the product of breeding male Brtl/+ with female WT.  8 
week old male WT and Brtl/+ mice were randomly assigned to SclAb (Scl-AbVI, Amgen, 
Thousand Oaks, CA) treatment or vehicle injection (PBS) with n=7/group.  Sclerostin antibody 
was injected subcutaneously at 25mg/kg, two times per week, for two weeks.  Calcein (30mg/kg) 
was injected at the start of experiment, after 1 week, and 1 day prior to sacrifice by 
intraperitoneal injection to facilitate dynamic histomorphometry and nanoindentation placement.  
Body weights were recorded with each injection.  Blood samples were collected at sacrifice by 
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intracardiac puncture, serum separated by centrifuge, and stored at -80˚C until analyzed by 
ELISA.  
Left femurs were collected for microCT and mechanical testing, and right femurs for 
dynamic histomorphometry and nanoindentation tests.  Both were stored at -20˚C in lactated 
ringers solution (LRS) soaked gauze until testing or further specimen preparation. All protocols 
and procedures involving animals were approved by the University of Michigan’s Committee on 
Use and Care of Animals. 
 
Serum Markers 
To measure osteoblast activity, serum osteocalcin (OCN) was quantified with a 
commercially available ELISA kit (BT-470, BTI, Stoughton, MA).  To quantify osteoclast 
number, serum TRACP5b was measured with a commercially available solid phase 
immunofixed enzyme activity assay (MouseTRAP, IDS, Fountain Hills, AZ).  Both serum tests 
were performed in duplicate. 
 
Micro Computed Tomography (µCT) 
Left femora were scanned in water using cone beam computed tomography (eXplore 
Locus SP, GE Healthcare Pre-Clinical Imaging, London, ON, Canada).  Scan parameters 
included a 0.5 degree increment angle, 4 frames averaged, an 80kVp and 80µA x-ray source with 
a 0.508mm Al filter to reduce beam hardening artifacts, and a beam flattener around the 
specimen holder [17].  All images were reconstructed and calibrated at an 18µm isotropic voxel 
size to a manufacturer supplied phantom of air, water and hydroxyapatite.  Regions of interest 
(ROI) were located for both cortical and trabecular parameters.  A diaphyseal cortical ROI 
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spanning 15% of total femur length was located midway between the distal growth plate and 
third trochanter.  Cortical bone was isolated with a fixed threshold of 2000 Hounsfield Units for 
all experimental groups.  Parameters including cortical thickness, cross sectional area, tissue 
mineral density (TMD), anterior-posterior bending moment of inertia, endosteal perimeter, and 
periosteal perimeter were quantified with commercially available software (MicroView v2.2 
Advanced Bone Analysis Application, GE Healthcare Pre-Clinical Imaging, London, ON, 
Canada).  A trabecular ROI 10% of total femur length was located immediately proximal to the 
distal femoral growth plate and defined along the inner cortical surface with a splining algorithm.  
Due to the different morphology induced by Scl-Ab treatment, a fixed threshold could not be 
utilized without bias.  Trabecular metaphyseal bone was isolated with a more conservative 
autothresholding algorithm for each specimen based on the bimodal distribution between marrow 
and bone [18].  Parameters including bone volume fraction (BV/TV), trabecular thickness 
(TbTh), and trabecular number (TbN) were quantified using standard stereology algorithms 
(MicroView v2.2).  A 3D sphere fitting algorithim was also used to confirm the stereology data 
for TbTh [19]. 
 
Mechanical Testing (Whole Bone) – Four-Point Bending 
Following µCT scanning, left femora were loaded to failure in four-point bending using a 
servohydraulic testing machine (MTS 858 MiniBionix, Eden Prarie, MN).  All specimens were 
kept hydrated in LRS-soaked gauze until mechanical testing.  In the same mid-diaphyseal region 
analyzed by µCT, the mid-diaphysis was loaded in four point bending with the posterior surface 
oriented under tension. The distance between the wide, upper supports was 6.26mm, and span 
between the narrow, lower supports 2.085mm.  The vertical displacement rate of the four-point 
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bending apparatus in the anterior-posterior direction was 0.5mm/sec. Force was recorded by a 
50lb load cell (Sensotec) and vertical displacement by an external linear variable differential 
transducer (LVDT, Lucas Schavitts, Hampton, VA), both at 2000Hz.  A custom MATLAB script 
was used to calculate stiffness, yield load, yield displacement, ultimate load, failure 
displacement, post-yield displacement, and energy to failure.  Combining anterior-posterior 
bending moment of inertia data from µCT with mechanical stiffness from four point bending, the 
estimated elastic modulus was calculated using standard beam theory as previously described 
[15]. 
 
Mechanical Testing (Tissue Level) – Fluorescent Guided Nanoindentation 
Right femora were dehydrated, encased in epoxy (Kold Mount, Vernon-Benshoff, 
Albany, NY), and cut transversely at the mid-diaphysis with a low-speed saw (IsoMet, Beuhler, 
Lake Bluff, IL). The distal section of tissue was polished using progressive grades of silicon 
carbide abrasive paper (1200, 2400, and 4000 grit) under water irrigation for two minutes at each 
grade.  To further decrease surface roughness the encased specimens were polished on a felt pad 
for 5 minutes with a ¼ µm diamond suspension (Streurs Inc., Cleveland, OH).  Specimens were 
then ultrasonically cleansed in a water bath for 10 minutes to remove surface debris, and glued to 
magnetic specimen plates for nanoindentation testing.  The final root mean square (RMS) 
roughness of the specimens’ surface was 10.0 ± 3.7 nm, as assessed with Scanning Probe 
Microscopy of a 5x5 µm
2
 region of the posterior mid cortex. 
A custom 950 TI TriboIndenter (Hysitron, Minneapolis, MN) instrumented with a 
fluorescent light-source and FITC filter allowed for simultaneous visualization of calcein 
labeling in specimens and accurate positioning of indents to locations matched for tissue age and 
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treatment status with 0.5µm spatial resolution. Four regions of interest were mechanically tested 
in the posterior aspect of the femoral cross section:  the mid-cortex (defined as midway between 
the first calcein label on the periosteal and endosteal surfaces, if any), along the first calcein label 
on 15 day old bone, along the second calcein label on 8 day old bone, and along the third and 
outer calcein label along 1 day old bone.  Indentation consisted of loading a diamond Berkovich 
indenter tip into samples at 300µN/s, hold at a maximal load of 3,000 µN for 10 s, and unload at 
300µN/s.  The indentation modulus E was calculated from the load-displacement curves using 
the standard Oliver-Pharr method [20]. Eight indents, 10 µm apart, were made along each calcein 
label and the mid cortex, with values averaged for each site and mouse.   
 
Dynamic Histomorphometry 
Using the same specimens tested by nanoindentation, dynamic histomorphometry was 
performed at the mid-diaphysis on the first and third labels according to standard nomenclature 
[21].  Briefly, fluorescent images were acquired using a Zeiss Axiovert 200M inverted 
microscope equipped with Apotome imaging system to minimize out-of-plane light, negating the 
need for several micron thin sections.  Fluorescent images were taken with a 10x objective of 
calcein (excitation 485/20nm, emission: 540/25nm) labels in bone.  The 10x images of the cortex 
were merged into a single image (Photoshop, Adobe), and these merged images were analyzed 
using commercially available software (Bioquant Osteo v7.20.10,  Nashville, TN).  Bone surface 
(BS), mineral apposition rate (MAR), mineralizing surface to bone surface (MS/BS), and bone 
formation rate (BFR) were quantified. 
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Statistics 
A multivariate ANOVA with LSD post-hoc was used to make all comparisons with the 
exception of nanoindentation data.  For nanoindentation data along calcein labels, a repeated 
measures ANOVA was used with genotype and treatment status as between-subjects factors and 
tissue age as the within-subjects factor with simple contrasts to mid-cortical reference values.  In 
all cases, p<0.05 was considered significant.  All data is presented as mean+S.D. 
 
Results  
Body Weight and Bone Length Remain Unchanged with Short-Term Sclerostin Antibody 
Treatment 
Consistent with the reduced body size with OI, body weight was significantly lower in 
male Brtl/+ (25.4±1.8g) compared to male WT mice (30.4±2.8g) at 8 weeks of age.  Twice 
weekly dosing of these mice with 25 mg/kg Scl-Ab for 2 weeks did not significantly change 
body weight gains (data not shown).  Scl-Ab treatment also had no effect on femoral length in 
WT mice (15.9±0.6mm vs 16.0±0.5mm Veh) or the shorter Brtl/+ mice (15.2±0.4mm vs 
15.5±0.4mm Veh) after 2 weeks.   
  
Serum Markers Show Brtl/+ Anabolic Response to Scl-Ab 
 Untreated Brtl/+ animals showed marginally elevated serum osteocalcin (p=0.060) and 
serum TRACP5b (p=0.083) relative to WT (Fig 2.1), consistent with reported increases in Brtl/+ 
bone turnover [16].  Scl-Ab therapy significantly increased serum osteocalcin in both WT and 
Brtl/+ (Fig 2.1), demonstrating a rapid systemic anabolic response to therapy.  Scl-Ab yielded 
trends toward reduced levels of serum TRACP5 in both WT (p=0.10) and Brtl/+ (p=0.082), 
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consistent with published reports observing reduced serum markers of bone resorption in rats and 
humans [8, 12].  
 
Scl-Ab Differentially Increases Cortical Bone Formation in Brtl/+ and WT  
At the femoral mid-shaft, Scl-Ab treatment increased periosteal BFR/BS in Brtl/+ and 
WT animals by 76% and 108% respectively (Fig. 2.2).  In Brtl/+, these increases were caused by 
a 50% increase in MS/BS, with no significant improvement in MAR.  Conversely, WT 
improvements in BFR/BS resulted from a significant 76% increase in MAR with no significant 
change in MS/BS.   
 
Scl-Ab Increases Trabecular Bone Apposition on Existing Bone Surfaces 
 Brtl/+ animals have lower BV/TV relative to WT caused by reduced trabecular number, 
but not thickness (Fig. 2.3, Fig 2.4).  Scl-Ab significantly increased distal femoral metaphyseal 
BV/TV in WT animals with a trend in Brtl/+ (p=0.077).  These improvements resulted from 
significant increases in trabecular thickness in both WT and Brtl/+, with no change in trabecular 
number in either genotype.  
 
Cortical Shape and Size, Not Mineralization, are Increased with Sclerostin Antibody 
 At the femoral mid-diaphysis, Brtl/+ animals have a reduced cortical thickness and area 
relative to WT as measured by microCT (Table 2.1).  Scl-Ab treatment significantly increased 
both cortical thickness and area in Brtl/+ and WT, primarily through increased femoral cortical 
periosteal perimeter.  Endocortical perimeter showed no significant differences with Scl-Ab 
treatment in either WT or Brtl/+. In combination, these individual factors contributed to 
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increasing trends in the anterior-posterior bending moment of inertia with Scl-Ab treatment in 
both WT and Brtl/+, reflecting a structurally stronger bone.  Mean cortical tissue mineralization 
(TMD) calculated by microCT was unaffected by Scl-Ab in either WT or Brtl/+.   
 
Sclerostin Antibody Improves Whole Bone Mechanical Properties 
 Brtl/+ femora have inherently lower ultimate load and stiffness (p=0.063) compared to 
WT (Table 2.1).  Two weeks of Scl-Ab treatment significantly increased ultimate load and 
stiffness in both WT and Brtl/+ mice.  The estimated tissue elastic modulus, as calculated by 
standard beam theory, was not affected by Scl-Ab treatment in WT or Brtl/+, corroborating 
similar findings in TMD.   
 A hallmark feature of OI bone is increased tissue brittleness.  Post-yield displacement 
(PYD) during four point bending is a measure of ductility, an inverse indicator of material 
brittleness.  Phenotypically, although Brtl/+ PYD was not significantly different that WT, five 
out of seven WT samples had a PYD greater than the largest Brtl/+ PYD value, consistent with 
previous reports increased brittleness at a similar age [15].  Unexpectedly, post yield 
displacement was increased 324% with Scl-Ab in WT (p<0.05), and 58% with Scl-Ab in Brtl/+, 
although failing to achieve statistical significance due to high variability.  These data suggest 
Scl-Ab reduced bone brittleness, improving bone ductility in both Brtl/+ and WT.   
 
Nanoindentation Reveals Similar Patterns of Mineralization in Scl-Ab Treated Animals 
 Nanoindentation measures local micromechanical properties associated with local tissue 
mineralization by measuring the tissue elastic modulus.  Phenotypically, in the overall statistical 
model, genotype was a significant predictor suggesting a greater tissue elastic modulus in Brtl/+ 
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compared to WT.  However, comparisons between genotypes at specific tissue ages were not 
significant.  Nanoindentation revealed that Scl-Ab treatment did not change the tissue elastic 
modulus of bone in either WT or Brtl.  This indicates that despite the sudden change in 
osteoblastic anabolic function with Scl-Ab treatment, no differences in tissue elastic modulus 
were seen in bone grown under the influence of Scl-Ab (Fig. 2.5).  The tissue age at which newly 
formed bone achieved mature tissue elastic modulus was rapid, as only bone laid down 1 day 
prior to euthanasia had a significantly reduced elastic modulus relative to mid-cortical values 
consistent with the rapid establishment of mechanical properties which has been reported in rats 
[22, 23].  No difference was found between 2 week old bone and 1 week old bone relative to 
mid-cortical values. 
 
Discussion 
 In this study, mice with a genetic knock-in that recreates a typical OI-causing mutation 
in type I collagen showed a positive response following short-term Scl-Ab therapy.  Two weeks 
of Scl-Ab significantly improved bone mass at both cortical and trabecular sites, and 
significantly reduced long bone fragility.  In the context of existing anabolic and anti-resorptive 
treatment options, Scl-Ab is novel and has high potential as a therapeutic for OI patients.  
Current anabolic treatment options have not shown uniform success when applied to OI.  The 
anabolic bone agent teraparatide is currently approved as an osteoporosis therapy, but has been 
associated with osteosarcoma after long term treatment in growing rats [24], and is therefore 
contraindicated for use in children with open growth plates.  Growth hormone has also been 
implemented as an anabolic therapy for OI.  While effective in some patients at increasing BMD 
as well as improving bone histomorphometry, the benefits are selective for patients who respond 
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to rGH with increased linear growth.  Other OI patients treated with rGH experience no positive 
effect, and may exacerbate their existing low bone mass phenotype by increasing osteoclast 
surface [25]. 
As a result of limited anabolic therapeutics, anti-resorptive bisphosphonates have been 
widely used in OI.  Several controlled pediatric OI clinical trials have demonstrated that 
bisphosphonate treatment is effective at increasing vertebral BMD [2–6].  Functionally, 
intravenous bisphosphonates are effective at increasing vertebral height, an indirect indicator of 
bone strength that suggests increased resistance to compression [3, 4]. However, in long bones a 
functional benefit is less clear, even in controlled trials up to 125 patients [1–6].   
 While bisphosphonate therapy increases areal BMD in pediatric OI populations, recent 
evidence suggests potential for several undesirable effects intrinsic to the BP mechanism of 
action.  First, BP binds strongly to the skeleton and has been detected in urinary markers 8 years 
after cessation of treatment, resulting in long term suppression of bone turnover [26]. Long-term 
BP therapy has been associated with the accumulation of microdamage in several animal models  
[27–31].  Brtl/+ mice have an increased propensity to form and accumulate microdamage [32] 
and thus BP treatment may potentially exacerbate this effect.  During growth, antiresorptive 
therapy results in retention of calcified cartilage near the growth plates.  This retention of 
primary spongiosa manifests radiographically as sclerotic metaphyseal banding coinciding with 
each BP treatment cycle, and these changes can bias measured BMD gains [33] without 
concomitant improvements in strength.  Previous studies of BP treatment in Brtl/+ found 
increased trabecular number, but not thickness [33].  Notably, in the present study with Scl-Ab, 
gains in trabecular bone mass resulted from increased trabecular thickness, not number. 
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In this study, we found that unlike WT osteoblasts, Brtl/+ osteoblasts did not increase 
their mineral apposition rate with Scl-Ab treatment.  This lack of an MAR increase in Brtl/+ may 
be suggestive of defective osteoblasts unable to keep pace with Scl-Ab-induced bone formation 
demands.  In support of this, Brtl/+ mice demonstrate a mild delay in secretion of collagen in cell 
culture, and an enlarged ER has been observed in Brtl/+ fibroblasts, suggesting ER-stress 
correlated with collagen production, and possibly degradation of mutant collagen [34].  Whether 
this result also exists in the various OI mouse models with different mutations will be important 
to contrast with the data presented here.  Alternatively, animal age and treatment duration of the 
Brtl/+ mouse model used in this study may also modulate any Scl-Ab induced MAR effect.  
Preliminary data from Brtl/+ mice treated for 5 weeks with Scl-Ab suggest an similar increase in 
MAR in both WT and Brtl/+ animals [35]. Regardless, it is important that Brtl/+ mice in this 
study were still able to increase bone formation rate in absence of MAR increases by increasing 
MS/BS at the periosteal cortical surface. 
 Unexpectedly, we found that Scl-Ab significantly reduced bone brittleness (increased 
post-yield displacement) in WT animals as measured by whole bone mechanical four-point 
bending.  Although reductions in bone brittleness were not statistically significant in Brtl/+ 
animals in this study, our finding of reduced brittleness in WT has broader implications about 
bone quality changes associated with Scl-Ab treatment.  While the differing bone geometries 
induced by Scl-Ab treatment raises the potential for experimental bias, the large magnitude of 
our observed difference in WT (324% increase in post yield displacement) remains suggestive.  
In contrast to the Scl-Ab data presented here, previous bisphosphonate treatment in Brtl/+ found 
neither significant changes nor increasing trends in PYD.  Moreover, BP-treated WT showed 
marginal reductions in PYD reflecting no improvements in bone brittleness with 
25 
 
bisphosphonates despite large gains in femoral bone mass [33].  Interestingly, in the contralateral 
femurs of the same animals which demonstrated reductions in post yield displacement, we did 
not observe any difference in the elastic modulus of bone formed under the influence of Scl-Ab 
by fluorescence guided nanoindentation.  These findings represent the first tissue level 
mechanical test of bone formed during Scl-Ab treatment through coupling of fluorescent imagng 
to nanoindentation.  Further studies are required to determine post-yield behavior of bone at the 
tissue level, unlike those reported in this study.   
 In summary, we have demonstrated that two weeks of Scl-Ab therapy was capable of 
increasing osteoblast activity in cells harboring a classical OI-causing Gly->Cys substitution in 
col1a1.  These gains lead to improved bone mass and whole bone mechanical properties without 
altering the timing of tissue mineralization.  While bisphosphonate therapy is in widespread use 
for pediatric OI patients, there is pressing need for more effective anabolic therapeutics to 
improve patient outcomes.  Scl-Ab is a unique and promising anabolic therapy which may be 
particularly useful for the treatment of pediatric OI.  The present data suggest Scl-Ab may be 
beneficial for the treatment of OI patients by stimulating the osteoblasts and reducing fracture 
risk.   
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Figure 2.1:  Serum TRACP5b and Osteocalcin.  Serum OCN (A) is elevated and serum 
TRACP5b (B) is reduced with Scl-Ab therapy in both WT and Brtl/+, suggesting a decoupled 
effect on bone formation and bone resorption.  In Vehicle treated animals, Brtl/+ trends toward 
higher OCN (A) and TRACP5b (B) levels suggesting increased bone turnover in Brtl/+.  * 
p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. Brtl/+ Veh.  
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Figure 2.2:  Cortical Dynamic Histomorphometry (Femur).  Dynamic histomorphometry at the 
periosteal femoral mid-diaphysis reveals anabolic effect of Scl-Ab in WT and Brtl/+.   Femoral 
cortical mid-diaphyseal periosteal BFR (A) increases with Scl-Ab are a result of increased 
periosteal MAR (B) in WT and periosteal MS/BS (C) in Brtl/+.  Brtl/+ Veh n=6, all other groups 
n=7.  * p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. Brtl/+ Veh.   
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Figure 2.3:  Femoral Trabecular MicroCT Representative Isosurfaces.  Micro computed 
tomography of the distal femur metaphysis reveals anabolic changes with Scl-Ab therapy.  
Representative microCT images of distal metaphyseal trabecular bone reflect these changes.  For 
each experimental group, the animal with the median BV/TV value is shown.  A conservative 
specimen specific threshold is applied as described in the methods.   
29 
 
 
Figure 2.4:  Femoral Trabecular MicroCT Data.  Micro computed tomography of the distal 
femur metaphysis reveals anabolic changes with Scl-Ab therapy.  BV/TV (A), and Tb.Th (B) 
were improved by Scl-Ab with no effect on Tb.N (C).  *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT 
Veh vs. Brtl/+ Veh.  
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Figure 2.5   Fluorescent Guided Nanoindentation of Scl-Ab Treated Bone.  Nanoindentation was 
performed along calcein labels to match tissue age between treated and untreated animals.  White 
Light, FITC, and merged images showing placement of indents (A).  Nanoindentation revealed 
no difference in tissue elastic modulus across treatment groups in WT (B) and Brtl/+ (C). *notes 
significance relative to mid-cortical reference and denotes p<0.05. 
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Table 2.1.  Cortical MicroCT and Mechanical Properties 
  
WT 
 Veh 
WT 
 Scl-Ab 
Brtl 
 Veh 
           Brtl 
        Scl-Ab 
Cortical Micro CT             
Thickness (mm) 0.21 ± .01 0.24 ± .01* 0.17 ± .02
#
  0.20 ± .02*
 
Cross Sectional Area (mm^2) 1.01 ± .10 1.16 ± .10* 0.76 ± .10
#
 0.91 ± .10* 
Endosteal Perimeter (mm) 4.51 ± .36 4.43 ± .22 4.09 ± .13
#
 4.21 ± .18  
Periosteal Perimeter (mm) 5.80 ± .42 5.95 ± .32 5.15 ± .16
#
 5.48 ± .21* 
Bending Moment  
    of Inertia (mm^4) 
0.21 ± .05 0.23 ± .04 0.12 ± .03
#
 0.16 ± .03
p=.08 
Tissue Mineral Density (mg/cm^3) 1052 ± 43 1051 ± 50 1081 ± 39 1092 ± 41  
Mechanical Four Point Bending             
Ultimate Load (N) 27.1 ± 4.5 38.7 ± 10.2* 18.2 ± 5.0
#
 26.8 ± 7.8* 
Stiffness (N/mm) 237 ± 28 297 ± 66* 192 ± 35
p=0.063
 256 ± 33* 
Energy to Failure (J) 3.1 ± 1.6 10.6 ± 7.6* 1.0 ± .6 2.0 ± 1.1 
Post Yield Displacement (mm) 0.058 ± .049 0.247 ± .143* 0.026 ± .021 0.041 ± .037  
Estimated Elastic Modulus (GPa) 4.6 ± 1.2 4.8 ± .5 6.0 ± 1.2
#
 6.0 ± .7  
 
Table 2.1.  Cortical MicroCT and Mechanical 4pt Bending.   Femoral mid-diaphyseal cortical 
microCT and mechanical four point bending data show increased cortical bone mass and strength 
with Scl-Ab.  *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. Brtl/+ Veh.   
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CHAPTER 3 
Adult Brtl/+ Mouse Model of Osteogenesis Imperfecta Demonstrates Anabolic  
Response to Sclerostin Antibody Treatment with Increased Bone Mass and Strength 
 
Introduction 
Osteogenesis imperfecta (OI) is a heritable disorder caused by mutations in type I 
collagen or collagen-associated proteins.  Patients with OI have increased bone fragility, causing 
fracture susceptibility from minimal force, skeletal deformities and growth deficiency [1].  OI is 
a disease that most severely affects children, and fracture rate tends to decrease after puberty.  
Despite this relative improvement, adults remain at an increased risk for fracture compared to a 
normal population, and commonly have osteoporotic BMD values [2].   
 Treatment options to improve bone strength in adults with OI include anti-resorptive 
bisphosphonates (BP) which are considered the current standard of care.  However, the limited 
clinical trials investigating BP use in adult OI have found mixed reports, with some studies citing 
a reduced fracture incidence with treatment, while others show no therapeutic effect despite 
increases in bone mass [3–6].  More effective therapies are needed for the treatment of adult OI 
and several preliminary reports have begun to investigate the use of anabolic teriparitide [7, 8]. 
Neutralizing antibodies to sclerostin are a novel anabolic osteoporosis treatment strategy 
presently in clinical trials for the treatment of osteoporosis, and may be useful for increasing 
bone mass in adult OI.  Sclerostin is a negative regulator of bone formation secreted primarily by 
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osteocytes which inhibits anabolic canonical wnt signaling in osteoblasts by binding to the 
LRP4/5/6 complex [9–11].  Treatment with a neutralizing antibody to sclerostin (Scl-Ab) 
prevents sclerostin inhibition of canonical wnt signaling and effectively reduces sclerostin’s 
ability to limit bone formation.  Scl-Ab has been shown to be highly anabolic in pre-clinical 
models of osteoporosis and in phase 1 and phase 2 clinical trials of men and postmenopausal 
women [12–15].  
The Brtl/+ mouse is a knock-in model for moderately severe Type IV OI with a G349C 
point mutation on col1a1 that recreates an identical defect found in an OI patient [16].  The 
Brtl/+ mouse recapitulates multiple features of the observed clinical phenotype including short 
stature, reduced BMD, increased bone brittleness, and impaired remodeling [17–19].  
Importantly, the Brtl/+ phenotype becomes less severe with age [17], making it an appropriate 
model for testing the anabolic efficacy of Scl-Ab in adult OI.   
We have previously reported that short-term Scl-Ab therapy is capable of stimulating 
bone formation and increasing bone mass in an 8 week old Brtl/+ model of OI [20].  Importantly, 
no preclinical studies have analyzed the effects of any anabolic or anti-catabolic agents in an 
adult model of OI.  The purpose of this study was to determine if Scl-Ab could increase bone 
formation in osteoblasts harboring a classical OI-causing mutation to improve bone mass and 
whole bone strength in an adult Brtl/+ model of OI. 
 
Materials and Methods 
Animals 
Wildtype (WT) and Brtl/+ mice are maintained on a mixed background of Sv129/CD-
1/C57BL/6S, and all Brtl/+ animals were the product of breeding male Brtl/+ with female WT.  6 
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month old male WT and Brtl/+ mice were randomly assigned to Scl-Ab (Scl-Ab VI, Amgen, 
Thousand Oaks, CA) treatment or vehicle injection (PBS) with WT Veh n=8, WT Scl-Ab n=9, 
Brtl/+ Veh n=8, and Brtl/+Scl-Ab =9.  Sclerostin antibody was injected subcutaneously at 
25mg/kg, two times per week, for five weeks, following the protocol described previously [13].  
To facilitate dynamic histomorphometry, calcein (30mg/kg, i.p.) was injected at the start of the 
experiment, 3 weeks before sac and 1 week before sac.  Alizarin (30mg/kg, i.p.) was injected 1 
day prior to sacrifice.  Body weights were recorded with each injection.  Blood samples were 
collected at euthanasia by intracardiac puncture, serum separated by centrifuge, and stored at -
80˚C until analyzed by ELISA.  
Left femurs were collected for microCT and mechanical testing, and right femurs for 
dynamic histomorphometry.  Both were stored at -20˚C in lactated ringers solution (LRS) soaked 
gauze until testing or further specimen preparation. All protocols and procedures involving 
animals were approved by the University of Michigan’s Committee on Use and Care of Animals. 
 
Serum Assays 
To measure osteoblast activity, serum osteocalcin (OCN) was quantified with a 
commercially available ELISA kit (BT-470, BTI, Stoughton, MA).  To quantify osteoclast 
number, serum TRACP5b was measured with a commercially available solid phase 
immunofixed enzyme activity assay (MouseTRAP, IDS, Fountain Hills, AZ).  Both serum tests 
were performed in duplicate. 
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MicroCT 
Left femora were scanned in water using cone beam computed tomography (eXplore 
Locus SP, GE Healthcare Pre-Clinical Imaging, London, ON, Canada).  Scan parameters 
included a 0.5 degree increment angle, 4 frames averaged, an 80kVp and 80µA x-ray source with 
a 0.508mm Al filter to reduce beam hardening artifacts, and a beam flattener around the 
specimen holder [21].  All images were reconstructed and calibrated at 18µm isotropic voxel size 
to a manufacturer supplied phantom of air, water and hydroxyapatite.  The entire femora was 
reoriented with the mid-diaphysis parallel to the z-axis, and bone length was measured as the 
distance between the most proximal and distal transverse plans containing the femur.  Regions of 
interest (ROI) were located for both cortical and trabecular parameters.  A diaphyseal cortical 
ROI spanning 15% of total femur length was located midway between the distal growth plate 
and third trochanter.  Cortical bone was isolated with a fixed threshold of 2000 Hounsfield Units 
for all experimental groups.  Parameters including cortical thickness, cross sectional area, tissue 
mineral density (TMD), bending moment of inertia in the anterior-posterior direction (about the 
medial-lateral axis), endosteal perimeter, and periosteal perimeter were quantified with 
commercially available software (MicroView v2.2 Advanced Bone Analysis Application, GE 
Healthcare Pre-Clinical Imaging, London, ON, Canada).  A trabecular ROI 10% of total femur 
length was located approximately 100 microns proximal to the central, and most proximal, 
portion of the distal femoral growth plate  The inner cortical surface was defined with a splining 
algorithm.  Due to the different morphology induced by Scl-Ab treatment, a fixed threshold 
could not be utilized without bias.  Trabecular metaphyseal bone was isolated with a more 
conservative autothresholding algorithm for each specimen based on the bimodal distribution 
between marrow and bone [22].  Parameters including bone volume fraction (BV/TV), trabecular 
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thickness (TbTh), and trabecular number (TbN) were quantified using standard stereology 
algorithms (MicroView v2.2).  A 3D sphere fitting algorithm was also used to confirm the 
stereology data for TbTh [23]. 
The 8
th
 caudal vertebrae were dissected and scanned with the same protocol as the 
femora.  Trabecular bone of the caudal vertebrae was analyzed in two ROIs, each spanning 9% 
of bone length and placed adjacent to the proximal and distal growth plates.  The trabecular 
surface was defined on the inner cortical surface with a splining algorithm.  Cortical bone of the 
8
th
 caudal vertebrae was analyzed in a ROI spanning 9% of bone length and placed in the middle 
of bone.  Cortical thickness was measured along four lines originating at the center of gravity of 
the section, and placed 40 and 50 degrees anterior to the medial lateral plane similar to previous 
reports [24]. 
 
Whole Bone Mechanical Four-Point Bending 
Following µCT scanning, left femora were loaded to failure in four-point bending using a 
servohydraulic testing machine (MTS 858 MiniBionix, Eden Prarie, MN).  All specimens were 
kept hydrated in LRS-soaked gauze until mechanical testing.  In the same mid-diaphyseal region 
analyzed by µCT, the mid-diaphysis was loaded in four point bending with the posterior surface 
oriented under tension. The distance between the wide, upper supports was 6.26mm, and span 
between the narrow, lower supports 2.085mm.  The vertical displacement rate of the four-point 
bending apparatus in the anterior-posterior direction was 0.5mm/sec. Force was recorded by a 
50lb load cell (Sensotec) and vertical displacement by an external linear variable differential 
transducer (LVDT, Lucas Schavitts, Hampton, VA), both at 2000Hz.  A custom MATLAB script 
was used to calculate all parameters measured from the force-displacement data.  Elastic energy 
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was defined as the area under the load-displacement curve prior to the yield point, and plastic 
energy was defined as the area under the load-displacement curve from the yield point until 
failure.  The yield point was defined as a 10% reduction in secant stiffness relative to the initial 
tangent stiffness.  Combining bending moment of inertia data from µCT with mechanical 
stiffness from four point bending, the estimated elastic modulus was calculated using standard 
beam theory as previously described [17]. 
 
Dynamic Histomorphometry 
Right femora were encased in epoxy (Kold Mount, Vernon-Benshoff, Albany, NY), and 
cut transversely with a low-speed saw (IsoMet, Beuhler, Lake Bluff, IL). The distal section of 
tissue was polished using progressive grades of silicon carbide abrasive paper (1200, 2400, and 
4000 grit) to a plane immediately distal to the third trochanter.   
Fluorescent images were acquired using a Zeiss Axiovert 200M inverted microscope 
equipped with a structured illumination (Apotome) imaging system.  This focuses the image on a 
specific plane, minimizes out-of-plane light, and negates the need for several micron thin 
sections.  Multiple fluorescent images were taken with a 10x objective of the calcein (excitation: 
485/20nm, emission: 540/25nm) and alizarin (excitation: 557/55nm, emission: 615nm) labels 
around the entire cortex.  The 10x images of the cortex were merged into a single image 
(Photoshop, Adobe), and these merged images were analyzed using commercially available 
software (Bioquant Osteo v7.20.10, Nashville, TN).  Bone surface (BS), mineral apposition rate 
(MAR), mineralizing surface to bone surface (MS/BS), and bone formation rate (BFR) were 
quantified on the calcein label given 3 weeks before sacrifice and the alizarin label given 1 day 
before sac on the periosteal surface and analyzed according to ASBMR standards [25]. 
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In order to quantify the level of cortical drift in these mice and contrast the therapeutic 
response to prior studies analyzing rapidly growing 3 week old Brtl/+ mice treated with Scl-Ab 
[26], dynamic histomorphometry outcomes were also assessed in anatomic regions around the 
cortex with a method similar to Bivi et. al [27].  The fluorescent images were oriented 
anatomically by using the contralateral microCT femoral 3D images as a reference.  The centroid 
of the fluorescent image was identified in ImageJ, and 110 degree angles from the centroid were 
used to define the anterior and posterior regions (Fig 3.5).  MAR, MS/BS, and cortical thickness 
were quantified in each of these anterior and posterior subregions.   
In any regions where there was no dual label, MAR was treated as a missing value.  For 
the purpose of calculating BFR/BS, a value of 0.1µm/day was assigned to MAR where missing 
values were present.  This value was determined from both looking at the biological limit 
observed in our specimens as well as values established in the literature [27].  BFR/BS was also 
analyzed when treated as a missing value.  One animal (WT Veh) had a missing fluorescent 
label, most likely due to injection error, and was excluded from this analysis.  Two additional 
animals (both WT Scl-Ab) displayed all fluorescent labels, but a portion of the endosteal surface 
had errors in image acquisition which could not be corrected.  Both of these animals were 
excluded from analysis on the endosteal surface only.  Final group sizes are shown in the 
relevant figures and tables. 
 
Statistics 
A two-factor multivariate ANOVA was performed for all data (IBM SPSS Statistics 
v21.0.0.0), the invididual factors as genotype (WT or Brtl/+) and treatment (Veh or Scl-Ab).  
The interaction term between genotype and treatment is also presented.  Tukey’s HSD post-hoc 
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test was used to make comparisons except when unequal variances were observed.  Dunnett’s T3 
post-hoc test was used for variables which displayed unequal variances.  In all cases, p<0.05 was 
considered significant.  Values between p=0.05 and p=0.10 are reported in all instances, and are 
referred to as “trends” in the text.  All data are presented as mean+S.D. 
 
Results 
Body Mass and Bone Length Not Changed by Scl-Ab 
At the beginning of the experiment, WT animals (38.4±4.1g) were significantly heavier 
than Brtl/+ (34.9±4.7g) when pooling data from Veh and Scl-Ab groups for each genotype.  
Throughout the 5 weeks of experiment, WT Veh and Brtl/+ Veh did not have any significant 
changes in body mass.  Scl-Ab did not induce a change in body mass during the 5 weeks of 
treatment (not shown).  
Brtl/+ Veh femurs were shorter than WT Veh as assessed by endpoint microCT (Table 
3.1).  Scl-Ab had no effect on femoral length. 
 
Scl-Ab Increased Serum Osteocalcin and Reduced Serum TRACP5b  
Scl-Ab significantly increased serum osteocalcin (OCN) levels in both WT (+49%) and 
Brtl/+ (+47%) indicative of increased bone formation and an anabolic response to therapy (Fig 
3.1).  Serum OCN levels were not different between Veh treated WT and Brtl/+ mice.   
Serum TRACP5b, a marker of osteoclast number, was significantly decreased in WT (-
78%).  Despite a numerical decrease in Brtl/+ (-66%) with Scl-Ab treatment, it was not 
statistically significant (p=0.064) (Fig 3.1).  The interaction term between genotype and 
treatment was not significant, suggesting that Scl-Ab did not have a differential effect on Serum 
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TRACP5b between WT and Brtl/+.  Similar to OCN data, there were no phenotypic differences 
observed between WT Veh and Brtl/+ Veh in serum TRACP5b. 
 
Scl-Ab Increases Femoral Trabecular Thickness and Trabecular Number 
Phenotypically, Brtl/+ Veh animals had reduced femoral trabecular BV/TV (Fig  3.2, Fig 
3.3) compared to WT Veh (-93%).  These differences were the result of significant reductions in 
trabecular number (-67%), but not trabecular thickness. 
In WT and Brtl/+, five weeks of Scl-Ab therapy significantly increased bone volume 
fraction (WT +117%; Brtl +119%) and trabecular BMD.  The significant gains in femoral 
trabecular bone mass with therapy were a result of significant increases in both trabecular 
thickness (WT +38%; Brtl +29%) and trabecular number (WT +70%; Brtl +55%). 
Despite these significant gains in the femur, we observed no effect of Scl-Ab on 
trabecular bone of the 8
th
 caudal vertebrae by microCT (Fig 3.4) 
 
Scl-Ab Increases Brtl/+ Bone Formation on Endosteal and Periosteal Femora Surfaces  
On the total periosteal surface of the diaphyseal femur, treatment of Brtl/+ with Scl-Ab 
significantly increased BFR/BS (+205%) as a result of large increases in MAR (+132%) and 
smaller gains in MS/BS (+38%) (Fig 3.5, Fig 3.6).   In WT animals, Scl-Ab significantly 
increased MAR (+114%) which led to an increase in BFR/BS (+169%).   Scl-Ab did not 
significantly increase MS/BS in WT on this surface even though 7 of 9 WT Scl-Ab animals had 
a MS/BS greater than the largest WT Veh value on the periosteal surface.  The interaction term 
was not significant, suggesting Scl-Ab did not behave differently for periosteal MS/BS between 
genotypes  On the total endosteal surface of both genotypes, Scl-Ab significantly increased 
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MS/BS (WT +181%; Brtl +155%) and MAR (WT +126%; Brtl +180%) to a similar extent.  
These gains led to large increases in endosteal BFR/BS in both genotypes with Scl-Ab treatment 
(WT +650%; Brtl +683%).  No differences were found between WT Veh and Brtl Veh on either 
surface, but overall Brtl/+ had greater endosteal MS/BS levels.    
Regional analysis in the anterior and posterior regions of the cortex revealed a weak 
posterior shifting cortical drift pattern in both WT Veh and Brtl/+ Veh with more bone formation 
observed on the posterior periosteal surface compared to the anterior periosteal surface (Fig 3.5, 
Table 3.2).  No complimentary cortical drift pattern was observed on the endosteal surface, 
where bone formation was very low in both genotypes. 
Analyzing the effect of Scl-Ab on the anterior and posterior sub-regions revealed a 
similar effect on the periosteal surface in each compartment, with BFR/BS gains primarily driven 
by increases in MAR (Table 3.2).  On the endosteal anterior and posterior surfaces, Scl-Ab 
increased MAR as well as MS/BS in Brtl/+, leading to increased BFR/BS. 
Analyzing BFR/BS data as a missing value when no MAR was present led to an identical 
statistical conclusion on the periosteal and endosteal surfaces (data not shown).  Two small 
statistical differences are apparent in the regional data on the low-forming endosteal posterior 
surface.  Specifically, when BFR/BS is treated as a missing value, WT Veh vs WT Scl-Ab 
becomes significant on the endosteal posterior surface, and is no longer significant (p=0.068) for 
Brtl/+ Veh vs Brtl/+ Scl-Ab. 
 
Scl-Ab Increases Brtl/+ Femoral Cortical Bone Mass  
Five weeks of Scl-Ab led to large increases in cortical cross-sectional area (WT +36%; 
Brtl +21%) and cortical thickness (WT +42%; Brtl +22%) in both genotypes (Table 3.1) as 
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measured by microCT of the left femora.  Consistent with the stronger endosteal vs periosteal 
response observed by dynamic histomorphometry, Scl-Ab significantly decreased marrow area 
in both genotypes (WT -11%; Brtl -19%), although total area and bending moment of inertia 
were unchanged.  A two-factor ANOVA revealed that overall Scl-Ab significantly increased the 
Bending Moment of Inertia and TMD, although the Scl-Ab effects were not significant within 
each genotype for these outcomes.   
No geometric phenotypic differences were observed between WT Veh and Brtl/+ Veh in 
the femoral cortex at this time point.  However, overall genotype effects from a two-factor 
ANOVA revealed that relative to WT, Brtl/+ had significantly reduced Marrow Area, 
significantly reduced Total Area, and significantly increased TMD.     
Consistent with a lack of effect in caudal vertebral trabecular bone, there was no effect of 
Scl-Ab on cortical thickness in either WT or Brtl/+ 8
th
 caudal vertebrae (Fig 3.4). 
 
Brtl/+ Whole Bone Mechanical Properties Improved by Scl-Ab 
Significant gains in whole bone mass with Scl-Ab led to significant improvements in 
whole bone mechanical properties as measured by mechanical four-point bending of the femoral 
mid-diaphysis (Fig 3.7, Table 3.1).  Specifically, five weeks of Scl-Ab caused large increases in 
Yield Load (WT +79%; Brtl +77%), Ultimate Load (WT +129%; Brtl +127%) and Bending 
Stiffness (WT +70%; Brtl +38%) in both genotypes (Table 3.1).  While increases in Energy-to-
Failure with Scl-Ab treatment were expected based on the effects on Ultimate Load, the 
magnitude of the increases were unexpected (WT +526%; Brtl +509%).  These observed 
increases in Energy-to-Failure with Scl-Ab were primarily a result of significantly increased 
plastic energy (WT +1498%; Brtl +1660%) and in lesser part a result of increased elastic energy 
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(WT +96%; Brtl +153%).  The increased plastic energy with Scl-Ab was a result of an increase 
in Post-Yield Displacement with therapy in both WT (+539%) and Brtl/+ (+541%) as 
demonstrated in the representative load-displacement curves in Figure 3.7.  Yield Displacement 
was increased in Brtl/+ with Scl-Ab, but not WT.  The estimated elastic modulus was increased 
with Scl-Ab in WT, but there was no effect in Brtl/+.  
Similar to cortical microCT data, there was no significant whole bone mechanical 
property phenotype of Brtl Veh vs WT Veh at this age.  However, overall genotype effects from 
a two-factor ANOVA revealed that relative to WT, Brtl/+ had significantly reduced Energy to 
Failure, and significantly increased Elastic Modulus.  
 
Discussion 
In this study, we demonstrated that five weeks of Scl-Ab therapy was able to stimulate 
bone formation in an adult Brtl/+ mouse model of Type IV OI, leading to increased long bone 
mass and improved mechanical properties.  No preclinical studies to date have analyzed the 
effect of pharmaceutical intervention for an adult mouse model of OI.  In the context of existing 
anabolic and anti-resorptive treatment options, Scl-Ab is a novel drug with strong therapeutic 
potential for adult OI patients.  While current treatment options to improve bone strength in 
adults with OI focus on bisphosphonates (BP), the functional benefit of antiresorptive therapy is 
appears modest.  A randomized control trial of intravenous neridronate in adults with Type IV OI 
found increased BMD at the spine and hip with treatment as well as reduced total fracture 
incidence [4].  In a randomized placebo-controlled trial of oral alendronate in patients with Type 
I OI, increased BMD at the spine and hip was observed with treatment, but the study was not 
powered to detect fracture risk [3].  Two more recent clinical trials have noted similar increases 
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in bone mass with BP treatment, but equivocal effects at reducing fractures in adults with OI [5, 
6].  Moreover, BP efficacy may be dependent upon the type and severity of OI [5] as well as the 
dose.  In light of these observations, strong motivation exists for the exploration of alternative 
therapies for the treatment of adult OI.  To address this need, recent studies have begun to 
investigate the use of anabolic intermittent parathyroid hormone as a therapy for adult OI.  An 
uncontrolled clinical trial indicates promising teriparatide efficacy in adult OI [7], and 
randomized double-blind placebo controlled trial also shows a benefit in Type I OI patients [8].  
Here, we noted suggestions of age-specific differences in response to Scl-Ab treatment, 
emphasizing the importance of examining adult OI mice separately from young OI mice.  
Rapidly growing 3 week Brtl/+ mice treated for 5 weeks with Scl-Ab showed a similar gain in 
femoral cortical bone area (WT +31%; Brtl/+ 25%) when compared to the adult data (WT +36%; 
Brtl/+ +21%) (Chapter 4).  Furthermore,  in the present study, we observed significant gains in 
femoral BV/TV in both WT and Brtl/+ with 5 weeks of Scl-Ab (Fig 3.2).  This contrasts with 
treatment of young Brtl/+ mice for an equivalent 5 weeks with Scl-Ab where we observed a 
more modest femoral trabecular response based on distance from the growth plate (Chapter 4). 
This data is suggestive of a differential trabecular response with age that may be related to 
differential turnover, altered sclerostin expression with growth, and perhaps the absence of 
confounding linear growth effects. 
While we expected Scl-Ab to increase femoral BV/TV in adult WT and Brtl/+ mice in 
this study by increasing trabecular thickness, we did not expect to see large changes in trabecular 
number.  Unexpectedly, we observed a large increase in trabecular number in the distal femoral 
metaphysis with five weeks of Scl-Ab (Fig 3.2).  Decreased bone resorption could explain this 
finding by preserving trabeculae that might otherwise be lost to increased primary trabecular 
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turnover.  In this study we found decreased serum TRACP5b with Scl-Ab, consistent with 
reports from others showing decreased bone resorption in humans [12] as well as preclinical 
rodent data [13].  Alternatively, the large differences in morphology induced by Scl-Ab could 
affect quantification of trabecular number.  If Veh animals contain trabeculae that were too thin 
to be detectable by microCT at the applied resolution, thickening of these structures to a 
detectable level by Scl-Ab could result in the increased trabecular number observed.  While our 
conservative specimen-specific thresholding method helps guard against these effects, it does not 
eliminate them.   
 Interestingly, we observed no effect of Scl-Ab on either the trabecular bone or cortical 
thickness of the 8
th
 caudal vertebrae in this study.  One previous study in adult female rats has 
observed an anabolic response with Scl-Ab in the caudal vertebrae [28].  Specifically, increases 
in BFR/BS and BV/TV were measured in sections by histomorphometry at this site of yellow 
marrow.  Interestingly, other studies of anabolic PTH have found reduced effects in the caudal 
vertebrae relative to the distal femur or lumbar vertebrae in ovariectomized rats with doses 20% 
of the present study [29].  Additional studies have observed a robust response to anabolic PTH in 
caudal vertebrae [30] while others have suggested that an anabolic PTH response in caudal 
vertebrae may be supported by mechanical loading [31].  Our lack of difference in BV/TV may 
reflect differences in local sclerostin expression or drug delivery in the caudal vertebrae,  as 
differences in the mouse compared to the rat, or dose of Scl-Ab. 
The femoral cortical dynamic histomorphometry response to Scl-Ab was also 
qualitatively different between the adult mice analyzed in this study and our treatment of rapidly 
growing 3 wk Brtl/+ mice.  In the present study, Scl-Ab was able to consistently increase MAR 
on the periosteal surface.  On the endosteal surface, where lower levels of bone formation were 
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found in control animals, Scl-Ab was able to increase both MS/BS and MAR in most cases.   
Previously, we reported that a short-term two week Scl-Ab therapy in 8 week old Brtl/+ mice 
stimulated femoral periosteal BFR by increasing mineralizing surface, but not mineral apposition 
rate [20].  In addition, we have also treated rapidly growing 3 wk old Brtl/+ mice for 5 weeks 
with Scl-Ab and similarly found that Scl-Ab was able to increase bone formation by primarily 
increasing MS/BS, with no effect on MAR on both the endosteal and periosteal surfaces [26].  
Although the cortical drift pattern we observed was weak in these 6 month old mice, the 
posterior periosteal surface remained a location of high bone formation (MS/BS) similar to our 
observation in rapidly growing 3 week old mice.  The regional dynamic histomorphometry 
analysis allows us conclude that Scl-Ab can increase MAR in regions that have high MS/BS in 
adult animals, but is unable to increase MAR in these regions in rapidly growing animals.  These 
findings may be related to different sclerostin expression levels with age, and a strong underlying 
cortical drift pattern in growing mice.  In addition, rapidly growing 3 wk mice have a high Veh 
MAR (~1.25-2.5µm/day) and may be operating at near maximum output, leaving little room for 
further stimulation via Scl-Ab.  In contrast, lower Veh MAR levels in adult 6 mo (~0.3µm/day) 
leave room for Scl-Ab to have a potent effect, and may explain the age-dependent effect of Scl-
Ab on MAR. 
 Increased tissue brittleness is a hallmark feature of the OI phenotype.  The Brtl/+ model 
demonstrates increased brittleness at young ages when mechanically tested to failure, and 
remains brittle through 6 months [17].  In this study, we observed that mid-diaphyseal cortical 
bone of the Brtl/+ femur had increased TMD, decreased energy to failure, and increased elastic 
modulus.  Previously, we found an unexpected result that a short-term treatment with Scl-Ab 
significantly increased Post-Yield Displacement (indicating decreased tissue brittleness) in WT 
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animals, but not Brtl/+ [20].  In the present study, we found exceptionally large gains in PYD 
with 5 weeks of Scl-Ab treatment in both WT and Brtl/+.  While we remain aware of the 
numerous violations of beam theory assumptions and loading differences that may result from 
Scl-Ab induced geometrical differences, the magnitude of the changes in PYD (WT +539%; Brtl 
+541%) is difficult to ignore.  The cause of this difference could be related to the addition of 
new, more ductile bone, to a mature skeleton.  Alternatively, it could reflect that bone formed 
under the influence of Scl-Ab may be of a different material independent of tissue age.  It will be 
important to determine if these reductions in brittleness are persistent changes, or transient 
changes that disappear quickly after cessation of therapy.  While the beneficial materials 
differences of Scl-Ab on PYD are suggestive, these data require corroboration with detailed 
composition and mechanical techniques.  Interestingly, we observed an increase in the estimated 
elastic modulus with Scl-Ab in WT, but not Brtl/+.  This finding was not accompanied by similar 
gains in tissue mineral density, suggesting that changes at a level of organization below that of 
overall cortical size, but larger than tissue ultrastructural characteristics may be at play.  
Alternatively, the robust changes in cortical thickness found with sclerostin antibody may induce 
additional artifact related to beam theory calculations, as has been previously described [32]. 
 There are several limitations of this study.  First, osteogenesis imperfecta is a 
heterogeneous disease with a wide range of phenotypes caused by many different mutations.  In 
this study, we used a mouse model harboring a mutation found in a patient with moderately 
severe Type IV OI.  The findings of this study in the Brtl/+ mouse may not apply to all mutations 
and types of OI, including recessive forms as well as those with null col1 alleles.  In addition, 
while Scl-Ab was potently anabolic in adult Brtl/+ mice is this study, it is unclear how long these 
gains will persist after cessation of therapy.  The Scl-Ab dose chosen for these studies was 
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consistent with prior pre-clinical ovariectomy studies modeling post-menopausal osteoporosis 
[15].   As drug pharmokinetics can vary greatly between human vs rodent, the human 
“equivalent” dose is not known, but we recognize that the 25mg/kg twice per week dose is likely 
higher than the currently proposed doses for humans.  
In summary, we have demonstrated that five weeks of Scl-Ab therapy was capable of 
increasing bone formation in an adult model of OI with a classic Gly->Cys substitution in 
col1a1.  OI is a disease that most severely affects children, and fracture rate tends to decrease 
after puberty.  Despite this relative improvement, adults remain at an increased risk for fracture 
compared to a normal population, and commonly have osteoporotic BMD values.  While 
bisphosphonate therapy is often used in adult OI patients, there is a need for more effective 
anabolic therapeutics to improve patient outcomes.  Scl-Ab is a unique and promising anabolic 
therapy which may be particularly useful for the treatment of adult OI by stimulating bone 
formation, adding bone mass, and increasing bone strength.    
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Figure 3.1:  Serum TRACP5b and Osteocalcin.  Serum OCN is elevated in both WT and Brtl/+ 
with Scl-Ab.  Serum TRACP5b is reduced with Scl-Ab therapy in WT and shows a trend 
(p=0.064) toward reduced levels in Brtl/+, suggesting a decoupled effect on bone formation and 
bone resorption.  * p<0.05 Scl-Ab vs. Veh. 
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Figure 3.2:  Femoral Trabecular MicroCT Representative Isosurfaces.   Micro computed 
tomography isosurface images of the distal femur metaphysis reveals anabolic changes with Scl-
Ab therapy.   
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Figure 3.3:  Femoral Trabecular MicroCT Data.  Micro computed tomography of the distal 
femur metaphysis reveals anabolic changes with Scl-Ab therapy.  BV/TV, Tb.Th, Tb.N, and Tb. 
BMD were increased with Scl-Ab in both WT and Brtl/+.   A conservative specimen specific 
threshold is applied as described in the methods. *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. 
Brtl/+ Veh.   
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Figure 3.4:  8th Caudal Vertebrae Trabecular and Cortical MicroCT Data.  MicroCT data from 
the 8
th
 caudal vertebra demonstrate no effect of sclerostin antibody on trabecular or cortical bone 
structure in Brtl/+ or WT mice.  
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Figure 3.5:  Representative Dynamic Histomorphometry and Regional Analysis Locations.  
Dynamic histomorphometry at the femoral mid-diaphysis reveals anabolic effect of Scl-Ab.  The 
centroid of the bone was located, and 110deg angles drawn to define the anterior and posterior 
regions of bone for the purpose of regional analysis shown in Table 3.2.  
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Figure 3.6:  Cortical Periosteal and Endosteal Dynamic Histomorphometry (Femur).  Dynamic 
histomorphometry at the femoral mid-diaphysis reveals anabolic effect of Scl-Ab in WT and 
Brtl/+.   The centroid of the bone was located, and 110deg angles drawn to define the anterior 
and posterior regions of bone.  Femoral cortical mid-diaphyseal periosteal BFR (A) increases 
with Scl-Ab are a result of increased periosteal MAR in WT and increased MAR and MS/BS in 
Brtl/+.  Endosteal BFR (B) increases with Scl-Ab as a result of increased endosteal MAR and 
MS/BS in both WT and Brtl/+.  * p<0.05 Scl-Ab vs. Veh.  
A B 
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Figure 3.7:  Representative Mechanical 4pt Bending Curves.  Representative load-displacement 
plots from 4pt bending data shown in Table 3.1 summarize Scl-Ab induced strength and changes 
in post-yield behavior with treatment. 
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Table 3.1.  Cortical MicroCT and Mechanical Properties    
  
WT 
 Veh  
WT 
 Scl-Ab 
 Brtl 
 Veh 
           Brtl 
        Scl-Ab             
Genotype 
p-value 
Treatment 
p-value 
Interaction 
p-value 
 n=8 n=8 n=7             n=9    
Cortical Micro CT             
   
Total Femur Length (mm) 16.71 ± .40 16.58 ± .28 15.51 ± 0.78
#
 15.91 ± .48 <0.001 0.454 0.150 
Thickness (mm) 0.201 ± .016 0.286 ± .028* 0.226 ± .028  0.277 ± .029*
 
0.412 <0.001 0.068 
Cross Sectional Area (mm^2) 0.97 ± .07 1.33 ± .14* 1.00 ± .19 1.21 ± .16* 0.413 <0.001 0.162 
Marrow Area (mm^2) 1.42 ± .16 1.15 ± .10* 1.16 ± .26 1.02 ± .11* <0.01 <0.01 0.254 
Total Area (mm^2) 2.39 ± .17 2.48 ± .16 2.16 ± .41 2.24 ± .22 <0.05 0.386 0.959 
Bending Moment  
    of Inertia (mm^4) 
0.19 ± .03 0.25 ± .04 0.17 ± .07 0.22 ± .06
 
0.185 <0.01 0.742 
Tissue Mineral Density (mg/cm^3) 1122 ± 40 1152 ± 33 1159 ± 38 1183 ± 32 <0.05 <0.05 0.806 
Mechanical Four Point Bending                
Yield Load (N) 19.9 ± 4.6 35.6 ± 7.5* 18.2 ± 6.7 32.2 ± 7.2* 0.286 <0.001 0.720 
Ultimate Load (N) 22.4 ± 3.5 51.5 ± 13.6* 19.4 ± 5.8 44.3 ± 4.9* 0.082 <0.001 0.458 
Stiffness (N/mm) 274 ± 39 467 ± 75* 311 ± 90 429 ± 66* 0.945 <0.001 0.139 
Energy to Failure (mJ) 1.1 ± 0.3 6.9 ± 3.5* 0.7 ± 0.3 4.2 ± 2.2* <0.05 <0.001 0.138 
Elastic Energy (mJ) 0.77 ± .32 1.51 ± 0.53* 0.53 ± .30 1.35 ± .55* 0.229 <0.001 0.807 
Plastic Energy (mJ) 0.33 ± .32 5.43 ± 3.26* 0.16 ± .33 2.90 ± 2.30* 0.073 <0.001 0.117 
Post Yield Displacement (mm) 0.019 ± .018 0.124 ± .07* 0.013 ± .024 0.083 ± .058* 0.183 <0.001 0.329 
Yield Displacement (mm) 0.066 ± .015 0.076 ± .012 0.052 ± .015 0.077 ± .017* 0.207 <0.01 0.161 
Estimated Elastic Modulus (GPa) 5.41 ± .78 7.07 ± 1.1* 7.30 ± 2.34 7.70 ± 1.98 0.042 0.091 0.293 
 
Table 3.1:  Cortical MicroCT and Mechanical 4pt Bending.  Femoral mid-diaphyseal cortical microCT and mechanical four point 
bending data reveal increased cortical bone mass and strength with Scl-Ab.   *p<0.05 Scl-Ab vs. Veh; 
#
p<0.05 WT Veh vs. Brtl/+ 
Veh.    
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Table 3.2.  Dynamic Histomorphometry on Femoral Cortical Subregions    
  
   WT 
  Veh 
             WT 
          Scl-Ab 
       Brtl/+ 
       Veh 
           Brtl/+ 
        Scl-Ab 
Genotype 
p-value 
Treatment 
p-value 
Interaction 
p-value 
Anterior             
   
   Cortical Thickness (µm) 192 ± 13 251 ± 27* 200 ± 17 232 ± 25*  0.485 <0.001 0.096 
   Periosteal MS/BS  0.69 ± .33 0.91 ± .10 0.57 ± .32 0.89 ± .16  0.425 <0.01 0.524 
   Periosteal MAR 0.16 ± .11 0.59 ± .14* 0.20 ± .09 0.52 ± .17*  0.710 <0.001 0.247 
   Periosteal BFR/BS 0.13 ± .12 0.53 ± .12* 0.11 ± .09 0.46 ± .15* 0.305 <0.001 0.517 
   Endosteal MS/BS 0.28 ± .16 0.79 ± .16* 0.36 ± .17 0.87 ± .10* 0.135 <0.001 0.939 
   Endosteal MAR 0.16 ± .01 0.53 ± .08* 0.14 ± .02 0.47 ± .12* 0.425 <0.001 0.717 
   Endosteal BFR/BS 0.04 ± .03 0.42 ± .13* 0.04 ± .02 0.41 ± .11* 0.837 <0.001 0.721 
                
Posterior                
   Cortical Thickness (µm) 216 ± 25 294 ± 46* 235 ±  40 309 ± 52*  0.262 <0.001 0.878 
   Periosteal MS/BS 0.92 ± .09 0.99 ± .02 0.83 ± .17 0.98 ± .02 0.133 <0.01 0.189 
   Periosteal MAR 0.44 ± .24 0.93 ± .16* 0.35 ± .23  0.90 ± .16*
 
0.422 <0.001 0.644 
   Periosteal BFR/BS 0.41 ± .21 0.91 ± .15* 0.31 ± .25 0.89 ± .17* 0.373 <0.001 0.604 
   Endosteal MS/BS 0.24 ± .10 0.67 ± .22* 0.33 ± .12 0.79 ± .16* 0.084 <0.001 0.825 
   Endosteal MAR 0.22 ± .07 0.80 ± .34 0.29 ±  .07 0.61 ± .14* 0.601 <0.01 0.303 
   Endosteal BFR/BS 0.04 ± .03 0.38 ± .37 0.05 ± .05 0.47 ± .10* 0.420 <0.001 0.590 
   
Table 3.2:  Regional Dynamic Histomorphometry.  Regional anterior-posterior femoral cortical dynamic histomorphometry analysis.  
Dual label was not present on all surfaces preventing MAR measurement in all samples.   
Anterior Periosteal MAR: WT Veh n=7, WT Scl-Ab n=9, Brtl/+ Veh n=7, Brtl/+ Scl-Ab n=9. 
Anterior Periosteal MS/BS, BFR/BS: WT Veh n=7, WT Scl-Ab n=9, Brtl/+ Veh n=8, Brtl/+ Scl-Ab n=9. 
Anterior Endosteal MAR:  WT Veh n=2, WT Scl-Ab n=7, Brtl/+ Veh n=2, Brtl/+ Scl-Ab n=9. 
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(Table 3.2 cont…) 
Anterior Endosteal MS/BS, BFR/BS:  WT Veh n=7, WT Scl-Ab n=7, Brtl/+ Veh n=8, Brtl/+ Scl-Ab n=9. 
Posterior Periosteal MAR. MS/BS, BFR/BS:  WT Veh n=7, WT Scl-Ab n=9, Brtl/+ Veh n=8, Brtl/+ Scl-Ab n=9. 
Posterior Endosteal MAR:  WT Veh n=2, WT Scl-Ab n=4, Brtl/+ Veh n=2, Brtl/+ Scl-Ab n=9. 
Posterior Endosteal MS/BS, BFR/BS:  WT Veh n=7, WT Scl-Ab n=7, Brtl/+ Veh n=8, Brtl/+ Scl-Ab n=9. 
*p<0.05 Scl-Ab vs. Veh, no phenotypic differences were observed.   
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CHAPTER 4 
Rapidly Growing Brtl/+ Mouse Model of Osteogenesis Imperfecta Improves Bone Mass 
and Strength with Sclerostin Antibody Treatment 
Introduction 
Osteogenesis imperfecta (OI) is a heritable collagen-related dysplasia that results in bone 
fragility [1].  This condition presents with a wide range of clinical severity, depending upon the 
type of OI and specific mutation.  While OI persists throughout life, the symptoms and fracture 
risk are greatest during childhood [2].  
Numerous therapies have been tried to reduce fracture risk in pediatric OI.  The most 
widely used treatment are anti-resorptive bisphosphonates.  Multiple clinical trials with pediatric 
OI and bisphosphonates have demonstrated their efficacy at increasing vertebral BMD and 
surrogate measures of vertebral strength; however, the effect on long bone fracture risk appears 
equivocal [3–8].  Treatment of pediatric OI with growth hormone (rGH) has shown encouraging 
results for an anabolic therapy, but was not consistently effective among all patients [9].  In 
positive responders, bone histology and mass were improved, and long bone fracture rates 
decreased, along with increased linear growth in some mildly and moderately severe pediatric OI 
patients [9, 10]. Intermittent PTH is not used in children before growth plate fusion because of a 
reported osteosarcoma risk in rats, and as a result is not available as a treatment for pediatric OI 
[11]. 
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Neutralizing antibodies to sclerostin are a candidate anabolic therapy for children with 
OI.  Sclerostin is a potent inhibitor of bone formation which is secreted primarily by osteocytes 
[12].  Broadly, sclerostin functions by inhibiting canonical Wnt signaling through its binding to 
the Wnt signaling co-receptors LRP5 and LRP6 present on cells of the osteoblast lineage [13].  
Neutralizing antibodies have been developed which functionally reduce sclerostin activity and 
thereby prevent sclerostin inhibition of bone formation.  An anabolic response to sclerostin 
antibodies has been demonstrated in numerous pre-clinical studies [14–17] as well as phase I and 
phase II trials of osteoporosis [18, 19]. 
The Brtl/+ mouse is heterozygous for a G349C mutation on col1a1 found in an OI 
patient, and is a model for moderately severe Type IV OI [20].  Brtl/+  recapitulates many of the 
phenotypic features of pediatric OI including small size, impaired remodeling, reduced 
trabecular and cortical bone mass, altered bone matrix structure, and impaired fracture mechanics 
[20–23].  As such, Brtl/+ has been used to explore multiple clinically relevant questions 
including fracture repair [24], bisphosphonate treatment [25], and cell therapies [26].  
Treatment of the rapidly growing skeleton of children with OI is the most clinically 
relevant time point.  Previously, we reported that a short-term, 2 week treatment of Brtl/+ with 
Scl-Ab successfully induced an anabolic response in 8 week old Brtl/+ mice [27].  While this 
proof-of-concept study demonstrated anabolic efficacy, it was not a direct correlate to the 
pediatric clinical condition, as mice only gained 2-5% body mass over the 2 weeks of treatment.  
In contrast, 3 wk old Brtl/+ mice in the present study more than doubled their body mass over the 
5 wk treatment duration, highlighting the large difference between these two ages.  To directly 
address whether Scl-Ab can elicit an anabolic response in an OI model during periods of rapid 
bone growth and body mass accrual, we treated rapidly growing 3 week old WT and Brtl/+ mice 
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for 5 weeks with Scl-Ab and hypothesized that therapy would lead to increased bone mass and 
strength by stimulating bone formation. 
 
Materials and Methods 
Animals 
Wildtype (WT) and Brtl/+ [20] mice are maintained on a mixed background of 
Sv129/CD-1/C57BL/6S, and all Brtl/+ animals were the product of breeding male heterozygous 
Brtl/+ with female WT.  3 week old male WT and Brtl/+ mice were randomly assigned to Scl-Ab 
(Scl-Ab VI, Amgen, Thousand Oaks, CA) treatment or vehicle injection (PBS) with n=8-
9/group.  Sclerostin antibody was injected subcutaneously at 25mg/kg, two times per week, for 
five weeks.  Calcein (30mg/kg, i.p. injection) was injected at the start of experiment (3 wks 
animal age), after 2 weeks of treatment (5 wks animal age), and after 4 weeks of treatment (7 
wks animals age).  A final alizarin label (30mg/kg, i.p. injection) was given 1 day before 
euthanasia (7wks + 6 days of animal age).  The multiple fluorescent labels were used to visualize 
the growth pattern during the entire course of therapy.  Body weights were recorded with each 
injection.  Blood samples were collected at sacrifice by intracardiac puncture, serum separated 
by centrifuge, and stored at -80˚C until analyzed by ELISA.   
Left femurs were collected for microCT and mechanical testing, and right femurs for 
dynamic histomorphometry.  Both were stored at -20˚C in lactated ringers solution (LRS) soaked 
gauze until testing or further specimen preparation. All protocols and procedures involving 
animals were approved by the University of Michigan’s Committee on Use and Care of Animals. 
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Bone Length and Growth 
 Left femur and tibia lengths were measured longitudinally using whole body radiographs 
taken at the beginning and end of experiments on Scl-Ab or Veh treated animals.  At 3 weeks of 
age, animals were briefly anesthetized with isoflurane, and microradiographs were taken in the 
coronal plane at 3x magnification (Faxitron MX-20, Faxitron X-Ray LLC, Lincolnshire, IL).  
Limbs were immobilized with tape during imaging to minimize motion and keep the leg bones 
flat.  At 8 weeks of age, the radiograph protocol was repeated immediately after sacrifice.  A lead 
ruler was used for calibration of the field of view, and bone lengths were measured with calipers.  
 
Serum Assays 
To measure osteoblast activity, serum osteocalcin (OCN) was quantified with a 
commercially available ELISA kit (BT-470, BTI, Stoughton, MA).  As a measure of osteoclast 
number, serum TRACP5b was measured with a commercially available solid phase 
immunofixed enzyme activity assay (MouseTRAP, IDS, Fountain Hills, AZ).  Both serum tests 
were performed in duplicate.  
  
MicroCT 
Left femora were scanned in water using cone beam computed tomography (eXplore 
Locus SP, GE Healthcare Pre-Clinical Imaging, London, ON, Canada).  Scan parameters 
included a 0.5 degree increment angle, 4 frames averaged, an 80kVp and 80µA x-ray source with 
a 0.508mm Al filter to reduce beam hardening artifacts, and a beam flattener around the 
specimen holder [28].  All images were reconstructed and calibrated at an 18µm isotropic voxel 
size to a manufacturer-supplied phantom of air, water and hydroxyapatite.  Regions of interest 
(ROI) were located for both cortical and trabecular parameters.  A diaphyseal cortical ROI 
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spanning 15% of total femur length was located midway between the distal growth plate and 
third trochanter.  Cortical bone was isolated with a fixed threshold of 2000 Hounsfield Units for 
all experimental groups.  Parameters including cortical thickness, cross sectional area, marrow 
area, total area, anterior-posterior bending moment of inertia and tissue mineral density (TMD) 
were quantified with commercially available software (MicroView v2.2 Advanced Bone 
Analysis Application, GE Healthcare Pre-Clinical Imaging, London, ON, Canada).  A trabecular 
ROI 10% of total femur length was located immediately proximal to the distal femoral growth 
plate and defined along the inner cortical surface with a splining algorithm.  Due to the different 
morphology induced by Scl-Ab treatment, a fixed threshold could not be utilized without bias.  
Trabecular metaphyseal bone was isolated with a more conservative autothresholding algorithm 
for each specimen based on the bimodal distribution between marrow and bone [29].  Parameters 
including bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular number 
(Tb.N), and trabecular bone mineral density (Tb.BMD) were quantified using standard 
stereology algorithms (MicroView v2.2).   
A qualitative difference in femoral trabecular bone morphology was noticed as a function 
of distance from the growth plate.  To quantify this, the 10% of bone length region of interest 
was sub-divided into the 5% of bone length region that was more distal (closer to the growth 
plate), and the 5% region that was more proximal.  The same threshold determined for the entire 
10% of bone length ROI was used for each of the 5% of bone length subdivided regions.  In this 
way, the relative contribution of each sub-region could be assessed.   
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Whole Bone Mechanical Four-Point Bending 
Following µCT scanning, left femora were loaded to failure in four-point bending using a 
servohydraulic testing machine (MTS 858 MiniBionix, Eden Prairie, MN).  All specimens were 
kept hydrated in LRS-soaked gauze until mechanical testing.  In the same mid-diaphyseal region 
analyzed by µCT, the femur was loaded in four point bending with the posterior surface oriented 
under tension. The distance between the wide, upper supports was 6.26mm, and span between 
the narrow, lower supports 2.085mm.  The vertical displacement rate of the four-point bending 
apparatus in the anterior-posterior direction was 0.5mm/sec. Force was recorded by a 50 lb load 
cell (Sensotec) and vertical displacement by an external linear variable differential transducer 
(LVDT, Lucas Schavitts, Hampton, VA), both at 2000Hz.  A custom MATLAB script was used 
to analyze the raw force-displacement data and calculate all four-point bending parameters.  
Combining anterior-posterior bending moment of inertia data from µCT with mechanical 
stiffness from four point bending, the estimated elastic modulus was calculated using standard 
beam theory as previously described [21]. 
 
Dynamic Histomorphometry 
Right femora were encased in epoxy (Kold Mount, Vernon-Benshoff, Albany, NY), and 
cut transversely with a low-speed saw (IsoMet, Beuhler, Lake Bluff, IL). The distal section of 
tissue was polished using progressive grades of silicon carbide abrasive paper (1200, 2400, and 
4000 grit) to a plane immediately distal to the third trochanter.  Specimens were further polished 
on a felt pad for 5 minutes with a ¼ µm diamond suspension (Struers Inc., Cleveland, OH).      
Fluorescent images were acquired using a Zeiss Axiovert 200M inverted microscope 
equipped with Apotome imaging system to minimize out-of-plane light, negating the need for 
several micron thin sections.  Multiple fluorescent images were taken with a 10x objective of the 
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calcein and alizarin labels around the entire cortex.  The 10x images of the cortex were merged 
into a single image (Photoshop, Adobe), and these merged images were analyzed using 
commercially available software (Bioquant Osteo v7.20.10, Nashville, TN).  Bone surface (BS), 
mineral apposition rate (MAR), mineralizing surface / bone surface (MS/BS), and bone 
formation rate / bone surface (BFR/BS) were quantified on both the periosteal and endosteal 
surfaces.  The final two labels, given 1 week and 1 day before sacrifice, were analyzed according 
to ASBMR standards [30].  
In order to examine the effect of Scl-Ab superimposed over a strong posterior shifting 
cortical drift pattern, dynamic histomorphometry outcomes were also assessed in anatomic 
regions around the cortex with a method similar to Bivi et. al [31].  The fluorescent images were 
oriented anatomically by using the contralateral microCT femoral 3D images as a reference.  The 
centroid of the fluorescent image was identified in ImageJ, and 110 degree angles from the 
centroid were used to define the anterior and posterior regions (Fig 4.5).  MAR, MS/BS, and 
cortical thickness were quantified in each of these anterior and posterior subregions. 
In any regions where there was no dual label, MAR was treated as a missing value.  For 
the purpose of calculating BFR/BS, a value of 0.3µm/day was assigned to MAR where missing 
values were present.  This value was determined from both looking at the biological limit 
observed in our specimens as well as values established in the literature [32]. 
 
Statistics 
A Kruskal-Wallis ANOVA and non-parametric Mann-U Whitney post-hoc tests were 
performed and p<0.05 was considered significant.  Values between p=0.05 and p=0.10 are 
reported in all instances.  Comparisons between WT Veh and Brtl/+ Scl-Ab were made for the 
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cortical microCT and mechanical four-point bending outcomes to assess the ability of Scl-Ab to 
restore the Brtl/+ phenotype to WT control levels.  Data is presented as mean+S.D. 
 
Results 
 
Scl-Ab Does Not Change Body Mass or Linear Growth Rates in Rapidly Growing Mice 
 Three week old mice are rapidly growing (Fig 4.1)  Throughout the five weeks of 
treatment, from 3 to 8 weeks of age, body mass was increased significantly by an average of 
87% in WT Veh and 121% in Brtl/+ Veh.  Consistent with previously reported phenotypic 
differences, Brtl/+ mice weigh less than WT (Fig. 4.1).  Brtl/+ Veh weighed 30% less than WT 
Veh (11.0±2.3g  vs. 15.8 ± 2.0g) at 3 weeks of age, and 22% less than WT Veh (23.9±3.8g vs. 
29.2±3.0g) at 8 weeks of age.  Both genotypes gained a similar amount of weight on an absolute 
basis (WT Veh 13.4±2.9g; Brtl/+ Veh 12.9±2.9g) over the 5 weeks of treatment.  Scl-Ab did not 
change the rate of body mass accrual throughout the treatment as weight gain was similar 
between Veh and Scl-Ab groups in both WT and Brtl/+.  As a result, body weight was similar at 
the end of experiment in both WT (WT Veh 29.2±3.0g vs. WT Scl-Ab 27.8±1.3g) and Brtl/+ 
(Brtl/+ Veh 23.9±3.8g vs. Brtl/+ Scl-Ab 24.1±2.5g) with therapy. 
 Reduced stature is a characteristic phenotype of OI patients.  To determine if Scl-Ab 
affected linear growth rate in animals that are rapidly growing, bone length was measured on X-
rays taken at the beginning and end of treatment.  (Table 4.1).  In the left tibia and femur, no 
difference in linear bone growth during treatment or overall endpoint bone length was observed 
with Scl-Ab in either WT or Brtl/+. Consistent with previously reported phenotypic differences, 
Brtl/+ bones were shorter than WT.
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Serum Osteocalcin is Elevated in Rapidly Growing Brtl/+  
Brtl/+ Veh had increased serum osteocalcin relative to WT Veh at 8 weeks of age (Fig. 
4.2).  Scl-Ab treatment did not significantly increase mean serum osteocalcin levels in either WT 
and Brtl/+.  No effect on serum TRACP5b levels was observed. 
 
Anabolic Scl-Ab Effect Depends on Distance of Trabecular Bone From Growth Plate 
Scl-Ab treatment increased femoral trabecular BV/TV by 57% in WT, but a significant 
effect was not observed in Brtl/+ (p=0.321) over the entire distal femoral 10% of bone length 
ROI (Fig. 4.3).  The Scl-Ab BV/TV gains in WT were a result of increases in both Tb.Th (+28%) 
and Tb.N (+22%).  Interestingly, despite the lack of Scl-Ab effect on BV/TV in Brtl/+, Tb.Th 
was significantly increased by a small amount (+8.7%). Tb.BMD demonstrated a similar pattern 
as BV/TV, with a significant (p<0.001) 67% increase observed in WT with Scl-Ab, but only a 
marginal 33% increasing trend observed in Brtl/+ (p=0.06). 
Despite this lack of effect over the entire distal femoral region, we observed a qualitative 
difference in the action of Scl-Ab as a function of distance from the distal femoral growth plate.  
To quantify this, we separated the 10% of bone length trabecular ROI into the 5% region closer 
to the growth plate and the 5% of bone length region farther from the growth plate (Fig 4.4). 
In the region closest to the growth plate we observed a significant gain in WT BV/TV 
with Scl-Ab treatment, but not in Brtl/+ (p=0.89).  The BV/TV gains in WT were a result of 
significant gains in Tb.Th (+49%), while Brtl only showed a modest trend towards increased 
Tb.Th (p=0.097).  There were no Tb.N changes with Scl-Ab observed in either genotype in this 
5% of bone length region closest to the growth plate.   
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In contrast, in the proximal 5% sub region further from the growth plate, Scl-Ab 
treatment resulted in a significant increase in BV/TV in both WT (126%) and Brtl/+ (69%) mice.  
In WT, BV/TV gains in this subregion were a result of significant gains in both Tb.Th (49%) and 
Tb.N (51%), while Brtl/+ only increased Tb.Th (29%), but not Tb.N.   
 
Scl-Ab Increases Cortical Bone Mass in Brtl/+ and WT by Similar Amounts 
Phenotypically, Brtl/+ Veh femoral bone had reduced cortical thickness (-18%), cross 
sectional area (-18%), and anterior-posterior bending moment of inertia (-31%) relative to WT 
Veh (Table 4.2).  The marrow area was not significantly different in Brtl/+ Veh animals, but total 
area was less than observed in WT Veh. 
Treatment with Scl-Ab significantly increased cortical thickness (WT +26%; Brtl/+ 
+24%) and cortical cross sectional area (WT +31%; Brtl/+ +25%) in both genotypes, leading to 
significantly increased anterior-posterior bending moment of inertia in both WT (+49%) and 
Brtl/+ (+30%).  These increases returned the Brtl/+ cortical geometric phenotype to levels not 
significantly different from WT Veh.  Neither marrow area nor total area were significantly 
altered by Scl-Ab in Brtl/+; WT yielded only a modest increasing trend (p=0.077) in total area 
with treatment.  Cortical TMD was increased in WT with Scl-Ab, and an increasing trend was 
observed in Brtl/+. 
 
Scl-Ab Rescues Reduced Brtl/+ Femoral Bone Strength to WT Veh Levels 
Phenotypically, Brtl/+ Veh had reduced mechanical properties compared to WT Veh 
(Table 4.2).  These included reduced strength outcomes such as Yield Load (-24%), Ultimate 
Load (-38%), Stiffness (-35%), and Energy to Failure (-60%).  In addition, Brtl/+ Veh also failed 
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in a more mechanically brittle manner than WT Veh.  This is evident in the decreased plastic 
energy (-75%), post yield displacement (-61%), and failure/yield displacement ratio (-39%).   
Scl-Ab therapy significantly increased most mechanical outcomes in both WT and Brtl/+.  
Specifically, Scl-Ab treatment increased Yield Load (WT +47%; Brtl +39%), Ultimate Load 
(WT +68%; Brtl +51%) and Stiffness (WT +55%; Brtl +61% ) in both genotypes, and in Brtl/+, 
restored these three parameters to the level of WT Veh.  Energy-To-Failure was significantly 
increased by Scl-Ab in WT (+303%), but only trended (p=0.093) with treatment in Brtl/+ 
(+42%).  This differential gain is caused by a genotype specific effect of Scl-Ab on bone 
brittleness.  In WT, the large increase in Energy-to-Failure with Scl-Ab was primarily due to a 
substantial increase in Plastic Energy (+386%).  The increased plastic energy was mostly due to 
increased Post Yield Displacement (+164%) in WT with Scl-Ab.  In contrast, Scl-Ab did not 
alter Plastic energy or Post Yield Displacement in Brtl/+.  Yield Displacement was not altered by 
Scl-Ab in either WT or Brtl/+.  The estimated elastic modulus was not significantly different. 
 
Regional Dynamic Histomorphometry Analysis Reveals Scl-Ab Action Superimposed over a  
Strong Cortical Drift Pattern 
In both WT Veh and Brtl/+ Veh there was a strong posterior shifting cortical drift pattern 
(Fig 4.5).  Specifically, we found high BFR/BS on the periosteal posterior and endosteal anterior 
bone, with over 90% of these surfaces forming bone in both genotypes.  Conversely, low bone 
formation rates were found on the periosteal anterior and endosteal posterior surfaces in both WT 
and Brtl/+ (Table 4.3).  
On the low bone forming posterior endosteal surface, Scl-Ab significantly increased 
MS/BS (WT +610%, Brtl +243%), which lead to increased BFR/BS (WT + 829%, Brtl/+ 
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+542%).  On the low bone forming periosteal anterior surface, Brtl/+ trended towards an 
increase in MS/BS, but this did not significantly change BFR/BS.  The Scl-Ab response was 
highly variable in WT animals on the low forming posterior endosteal surface. 
On the high bone forming surfaces, Scl-Ab had no effect on dynamic histomorphometry 
outcomes in either genotype.  Specifically, on the periosteal posterior surface, no significant 
differences were observed for MS/BS, MAR, or BFR/BS in either WT or Brtl/+.  On the high 
bone forming endosteal anterior surface, Scl-Ab resulted in an unexpected trend towards reduced 
MAR (p=0.094) during the last week of treatment, but this did lead to a change in BFR/BS.  No 
changes in WT endosteal anterior surface were observed with Scl-Ab.  
These regional changes with sclerostin antibody were sufficient to significantly increase 
cortical thickness in both WT and Brtl/+ on the anterior (WT +19%; Brtl/+ +23%) and posterior 
(WT +25%; Brtl/+ +32%) surfaces after 5 weeks of treatment.  However, due to the regional 
nature of the underlying cortical drift pattern, Scl-Ab treatment did not result in any significant 
changes in overall periosteal MAR, MS/BS, or BFR/BS in either WT or Brtl/+ when summed 
over the entire periosteal surface (Table 4.3).  The total endosteal surface showed a more robust 
response to therapy.  In Brtl/+, treatment with Scl-Ab significantly increased total endosteal 
MS/BS (28%).  In WT, Scl-Ab had opposing effects of significantly reducing total endosteal 
MAR (-24%) while increasing total endosteal MS/BS (+61%).  The relatively larger gains in WT 
MS/BS led to an increasing trend (p=0.094) in total endosteal BFR/BS with treatment. 
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Discussion 
This study demonstrated that Scl-Ab increased bone formation leading to improved bone 
mass and strength in a rapidly growing Brtl/+ mouse model of moderately severe Type IV OI.  
Impressively, treatment with Scl-Ab significantly improved long bone strength to levels not 
significantly different than WT and rescued the Brtl/+ phenotype of reduced bone mass.  This 
potent effect of Scl-Ab on cortical bone mass and long bone strength starkly contrasts with the 
existing bisphosphonate data reported in both animal models and clinical studies.  Previously, we 
examined the effect of alendronate treatment of the Brtl/+ mouse during growth [25].  While 
alendronate treatment of Brtl/+ between 2-8 weeks of age resulted in extremely large gains in 
femoral metaphyseal bone mass, alendronate had little effect on cortical bone mass and strength, 
which required a full 12 weeks of treatment to show a modest effect.  The absence of a strong 
alendronate effect on OI cortical bone is not specific to the Brtl/+ mouse model and similar data 
has been observed in other OI mouse models such as oim [33].  This observation of a reduced or 
absent effect of bisphosphonate on OI cortical bone mass is also reflected in clinical data.  The 
controlled clinical trials of bisphosphonates in pediatric OI suggest a beneficial effect on 
vertebral trabecular bone but an equivocal effect on long bone strength [3–7].  Therefore, a 
therapy which consistently increases long bone strength in pediatric OI is currently lacking.  The 
current study suggests that Scl-Ab may provide a novel and unique therapeutic option for 
pediatric OI by reducing long-bone susceptibility to fracture.   
The underlying cause of classical OI fragility is that a collagen structural defect produces 
bone of both reduced material quality as well as reduced bone mass.  In this study, Scl-Ab was 
able to significantly improve femoral strength by increasing bone mass without altering the 
underlying brittle nature of the material.  Specifically, Scl-Ab was able to increase cortical bone 
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mass in Brtl/+ by significantly increasing cortical thickness (+24%) and cortical area (+25%).  
Although the unchanged post-yield displacement in Brtl/+ with Scl-Ab treatment suggests that 
Scl-Ab did not improve the inherent brittle material behavior of Brtl/+ bone, Scl-Ab did 
significantly improve long bone strength by increasing cortical bone mass, making the bone less 
fragile.  A trend towards increased cortical TMD with Scl-Ab in Brtl/+ could be suggestive of 
increased mineralization, but this finding did not correlate with the estimated elastic modulus as 
measured by four-point bending.  Rather, this increase could be a result of porosity changes 
below the resolution of our microCT, or partial volume effects, both of which could artificially 
increase this index of bone mineralization.  
In this study, the Brtl/+ trabecular response to Scl-Ab in the distal femur was notably less 
robust than in WT.  Trabecular thickness increased after 5 weeks of Scl-Ab treatment in both 
WT and Brtl/+, confirming our previous work where Brtl/+ was treated between 8-10 weeks of 
age [27].  In both studies, BV/TV was not significantly increased in Brtl/+.  However, the 
extended 5 week treatment duration of the present study allowed us to discriminate more subtle 
treatment effects, and further analysis revealed a significant anabolic BV/TV response in the 
Brtl/+ Scl-Ab group in a more proximal subregion of the femur metaphysis.  The lesser gains in 
bone mass near the growth plate in both genotypes may be related to the shorter duration of Scl-
Ab exposure to this newly formed bone.  In addition, the function of sclerostin near the growth 
plate may be reduced and not critical to the initial patterning of trabeculae.  However, this would 
not explain the differential Scl-Ab response we observed in Brtl/+ vs. WT.  The reduced 
trabecular response to Scl-Ab in Brtl/+ may be a result of increased bone resorption levels in 
Brtl/+ animals [22] which may mask equivalent bone formation responses, although we did not 
observe significant serum TRACP5b differences in this study.  Alternatively, there may be a 
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reduced anabolic response to Scl-Ab in Brtl/+ trabecular bone compared to WT which may be a 
result of differential sclerostin levels or impaired osteoblast function.   
The reduced Brtl/+ femoral trabecular response observed in this study contrasts with the 
robust Scl-Ab increases in cortical bone mass in both WT and Brtl/+.  Furthermore, these 
findings also contrast with our observations studying adult 6 month old Brtl/+ mice that were 
treated for 5 weeks with Scl-Ab [34].  In these adult mice, we observed significant BV/TV gains 
in both WT and Brtl/+ using an identical Scl-Ab treatment period and microCT methodology.  
Furthermore, serum results from the present study contrast with our prior reports of a strong 
anabolic serum response shown in short term treatment [27] and 5 weeks of Scl-Ab treatment in 
6 month old Brtl/+ mice [34].  This suggests a potential age dependent response to Scl-Ab that 
must be considered in greater detail before undertaking the translation of Scl-Ab to pediatric OI 
patients.   
Patients with OI often have severely reduced stature.  To examine if Scl-Ab treatment 
altered linear growth rates during this phase of rapid growth of the Brtl/+ mouse we examined 
pre- and post- treatment bone lengths by X-ray.    Here, we found no significant effects of 
treatment on long bone length after 5 weeks of therapy, consistent with prior reports of neutral 
effects of Scl-Ab on bone length in 7 week old mice [35].  While Scl-Ab appears promising for 
increasing bone mass, it does not appear to increase the short stature phenotypic of Brtl/+ OI 
mice.  However, the lack of a bone length increase in mice does not necessarily preclude an 
effect in humans; SOST KO mice do not have longer bones [36] but patients with sclerosteosis 
do have increased stature [37].   
We observed a mechanistic difference between increasing MAR on existing bone 
formation surfaces, and stimulating new bone formation on otherwise quiescent or resorbing 
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bone surfaces.  The regional anterior/posterior dynamic histomorphometry analysis performed in 
this study helps to separate these two effects by analyzing the superposition of a strong 
underlying cortical drift pattern characteristic of young animals [38, 39] with a potent anabolic 
therapy.  Scl-Ab activated bone formation surfaces on quiescent or low bone forming surfaces in 
Brtl/+ and WT mice, with minimal additional effect on increasing osteoblast activity on surfaces 
with already high levels of bone formation.  These findings may have important clinical impact 
when considering where Scl-Ab may have its most potent effects during growth and 
development, and where its effect may be limited, perhaps due to already high levels of bone 
formation.   
The regional dynamic histomorphometry responses to Scl-Ab treatment were not always 
consistent within experimental group.  For example, on the anterior periosteal surface where no 
bone formation was observed in WT Veh controls, the bone formation response to Scl-Ab was 
either robust or non-existent.  Specifically, Scl-Ab activated bone formation in only 3 of the 8 
mice in the WT Scl-Ab group.  Moreover, these three mice had MS/BS values that were greater 
than 0.95, highlighting the strong anabolic response in this subset of animals.  The 5 out of 8 
mice that did not respond had no fluorescent labeling on this surface, and an MS/BS of zero.   
The changes in cortical thickness in the posterior compartment of the femoral cortex are 
likely due to the strong endosteal BFR/BS response to therapy (Table 4.3).  However, the 
significant increases in anterior femoral thickness are not easily explained by regional response 
differences, as no significant differences in BFR/BS occurred in either genotype with Scl-Ab.  It 
is possible that Scl-Ab treatment reduced bone resorption on the periosteal anterior surface, 
which would increase cortical thickness.  Another possibility is that significant gains in bone 
formation with Scl-Ab occurred in the anterior compartment before the last week of treatment.  
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Finally, we were able to measure cortical thickness in all specimens (n=8-9/group) allowing for 
greater statistical power, but had slightly smaller group sizes for the dynamic histomorphometry 
outcomes due to missed injections of fluorescent label (n=7-8). 
This study has several limitations.  First, despite the fact that the Brtl/+ mouse was made 
to have a mutation identical to that found in a Type IV OI patient, it does not fully recapitulate 
the phenotype of humans and suffer spontaneous fractures.  In addition, as OI is a disease of 
many mutations, the results of this study may not extend to all types of OI.  Before considering 
translation to humans, future studies need to analyze the potential effect of sclerostin inhibition 
on skeletal overgrowth in undesired locations apparent in human diseases of sclerostin deficiency 
[40] 
In summary, Scl-Ab significantly increased bone formation, bone mass, and long bone 
strength in growing mice with a typical OI-causing mutation in type I collagen during a period of 
rapid bone mass accrual. These results contrast with existing bisphosphonate treatment strategies 
which have not demonstrated convincing improvements in long bone fragility in pre-clinical 
models or clinical trials.  On bone surfaces where osteoblasts were highly active in rapidly 
growing animals in this study, Scl-Ab had a minimal additional anabolic effect.  Rather, 
increased anabolic activity resulted from activation of quiescent or resorbing surfaces.  These 
observations, along with regional improvements in trabecular bone mass associated with tissue 
age reflect the necessity of testing anabolic agents during periods of rapid growth to prepare for 
pediatric indications. The current data suggest that Scl-Ab may be a candidate pharmacologic for 
the treatment of pediatric osteogenesis imperfecta.    
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Figure 4.1.  Body Mass Over from 3wks to 8wks of Age.  Body mass curves throughout the 
course of experiment from 3 wks of age to 8 wks of age confirm that Brtl/+ animals are lighter 
than WT and reveal Scl-Ab does not effect body mass.  Data are n=8-9/group. 
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Figure 4.2.  Serum TRACP5b and Osteocalcin.  Serum osteocalcin is significantly greater in 
Brtl/+ Veh vs. WT Veh, but no significant effect of Scl-Ab on serum osteocalcin is observed in 
either genotype.  The inability to obtain serum samples from all animals results in a slight 
reduction in group sizes.  For OCN:  WT Veh n=6, WT Scl-Ab n= 9; Brtl/+ Veh n =6, Brtl/+ 
Scl-Ab n=6.  For TRACP5b:  WT Veh n=9, WT Scl-Ab n= 9; Brtl/+ Veh n=7, Brtl/+ Scl-Ab 
n=7.
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Figure 4.3.  Femoral Trabecular MicroCT Isosurface and Data.  Micro computed tomography of 
the distal femur metaphysis reveals anabolic changes with Scl-Ab therapy.  The ROI (A) was 
10% of bone length and placed immediately proximal to the growth plate.  Representative 
median BV/TV isosurface images (B) reveal a qualitative reduction in Brtl/+ bone mass and the 
anabolic effect of Scl-Ab therapy.  Quantitative analysis (C) reveals a reduction in Brtl/+ BV/TV 
as a result of decreased trabecular number.  Scl-Ab significantly increased trabecular number and 
thickness in WT, leading to increased BV/TV.  In Brtl/+, Scl-Ab increased trabecular thickness 
but did not alter trabecular number or BV/TV.  There was a trend (p=0.06) towards increased 
trabecular BMD in Brtl/+ with Scl-Ab.  *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. Brtl/+ 
Veh.  Data are n=8-9/group. 
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Figure 4.4. Femoral Trabecular MicroCT Proximal and Distal Sub-region Analysis.  Differential 
response of Scl-Ab on trabecular bone mass as a function of distance from the growth plate.  The 
trabecular 10% ROI shown in Fig 3A was separated into proximal (A) and distal(C) 5% on bone 
length subregions.  In the proximal compartment (B), we found that Scl-Ab significantly 
improved trabecular BV/TV and thickness in both WT and Brtl/+.  In the distal ROI (D), there 
were few genotype differences and Scl-Ab increased BV/TV and trabecular thickness in WT, but 
had little effect on Brtl/+.  *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. Brtl/+ Veh.  Data are 
n=8-9/group. 
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Figure 4.5.  Representative Dynamic Histomorphometry and Regional Analysis Locations.  
Representative dynamic histomorphometry images of a Brtl/+ Veh animal showing a strong 
posterior shifting cortical drift pattern and the bone formation induced by Scl-Ab.  In all samples, 
the centroid of the bone was located, and 110° angles drawn to define the anterior and posterior 
regions of bone.  These subregions were used to define the anterior-posterior cortical drift 
dynamic histomorphometry response shown in Table 4.3. 
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Table 4.1.  Linear Bone Growth as Measured by Pre and Post Treatment X-ray 
  
   WT 
  Veh 
             WT 
          Scl-Ab 
       Brtl 
       Veh 
           Brtl/+ 
        Scl-Ab 
Left Femur             
Length at 3 weeks of age (mm) 11.43 ± .43 11.34 ± .42 10.25 ± .80 
#
 10.49 ± .39
 
Length at 8 weeks of age (mm) 14.00 ± .43 14.25 ± .33 13.03 ± .90 
#
 13.10 ± .58 
Paired percent bone growth (%) 22.5 ± 3.4 25.8 ± 4.1  27.3 ± 3.3  24.9 ± 4.1 
Left Tibia             
Length at 3 weeks of age (mm) 14.72 ± .37 14.67 ± .57 13.44 ± .75 
#
 13.55 ± .77
 
Length at 8 weeks of age (mm) 17.50 ± .42 17.31 ± .45 16.29 ± .70 
#
 16.44 ± .42 
Paired percent bone growth (%) 19.0 ± 3.1 18.1 ± 2.8 21.4 ± 4.0  21.6 ± 5.1 
 
Table 4.1.  Linear Bone Growth Rates of Femur and Tibia.  Linear bone growth of the femur and 
tibia from 3 wks to 8 wks of age as assessed by microradiograph.  *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. Brtl/+ Veh.  Data are n=8-9/group. 
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Table 4.2.  Cortical MicroCT and Mechanical Properties 
  
WT 
 Veh 
WT 
 Scl-Ab 
Brtl/+ 
 Veh 
           Brtl/+ 
        Scl-Ab 
Cortical Micro CT             
Thickness (mm) 0.20 ± .01 0.25 ± .03
*
 0.16 ± .02 
#
 0.20 ± .01
* 
Cross Sectional Area (mm^2) 0.91 ± .07 1.19 ± .22
*
 0.71 ± .10
#
 0.89 ± .08
*
 
Marrow Area (mm^2) 1.30 ± .17 1.33 ± .18 1.20 ± .08 1.17 ± .15 
Total Area (mm^2) 2.21 ± .22 2.53 ± .40
p=0.077
 1.91 ± .16
#
 2.06 ± .21 
Bending Moment  
    of Inertia (mm^4) 
0.17 ± .03 0.26 ± .09
*
 0.12 ± .02
#
 0.16 ± .03
* 
Tissue Mineral Density (mg/cm^3) 1017 ± 35 1046 ± 33
*
 1004 ± 48 1054 ± 47
p=0.059, +
 
Mechanical Four Point Bending             
Yield Load (N) 19.7 ± 3.2 28.8 ± 5.3
*
 15.0 ± 3.1
#
 20.8 ± 3.3
*
 
Ultimate Load (N) 27.6 ± 2.4 46.4 ± 10.8
*
 17.0 ± 3.6
#
 25.6 ± 3.9
*
 
Stiffness (N/mm) 198 ± 25 308 ± 71
*
 129 ± 30
#
 208 ± 32
*
 
Energy to Failure (mJ) 4.6 ± 1.5 18.4 ± 12.4
*
 1.8 ± 1.0
#
 2.6 ± 1.0
p=0.093,+
 
Elastic Energy (mJ) 1.10 ± .30 1.55 ± .41
*
 0.95 ± .22 1.19 ± .36 
Plastic Energy (mJ) 3.5 ± 1.5 16.8 ± 12.3
*
 0.88 ± .92
#
 1.4 ± 1.1
+
 
Yield Displacement (mm) 0.109 ± .013 0.112 ± .022 0.129 ± .027 0.116 ± .023 
Post Yield Displacement (mm) 0.144 ± .058 0.380 ± .198
*
 0.056 ± .059
#
 0.062 ± .042
+
 
Fail/Yield Displacement Ratio 2.32 ± .51 4.65 ± 2.37
*
 1.42 ± .44
#
 1.59 ± .46
+
 
Estimated Elastic Modulus (GPa) 4.46 ± .73 4.79 ± 1.07 4.05 ± .48 5.16 ± 1.09 
 
Table 4.2.  Cortical MicroCT and Mechanical 4pt Bending.  Data collected at femoral mid-
diaphysis show increased bone mass and strength with Scl-Ab.  *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 WT Veh vs. Brtl/+ Veh; 
+
p<0.05 WT Veh vs. Brtl/+ Scl-Ab.  Data are n=8-9/group. 
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Table 4.3.  Dynamic Histomorphometry on Femoral Cortical Subregions 
  
   WT 
  Veh 
             WT 
          Scl-Ab 
       Brtl/+ 
       Veh 
           Brtl/+ 
        Scl-Ab 
Anterior             
  Cortical Thickness (µm) 182 ±  17 217 ±  27* 158 ±  21
#
 194 ±  17*  
  Periosteal MS/BS  0.00 ± .00 0.36 ± .51 0.43 ± .25
#
 0.73 ± .28
 p=0.094
  
  Periosteal MAR NA ± NA 1.31 ± .56 1.18 ± .98 1.14 ± .48  
  Periosteal BFR/BS 0.00 ± .00 0.48 ± .73 0.59 ± .78
#
 0.85 ± .46 
  Endosteal MS/BS 0.91 ± .20 0.96 ± .04 0.93 ± .09 0.86 ± .09 
  Endosteal MAR 2.06 ± .29 1.66 ± .61 1.36 ± .51
#
 0.96 ± .39
 p=0.094
 
  Endosteal BFR/BS 1.76 ± .75 1.59 ± .56 1.28 ± .52 0.81 ± .40 
Posterior             
   Cortical Thickness (µm) 213 ±  15 267 ±  41* 178 ±  29
#
 235 ±  19*  
   Periosteal MS/BS 0.94 ± .09 0.99 ± .01 0.99 ± .01 0.98 ± .02 
   Periosteal MAR 1.90 ± .54 2.38 ± .77 2.11 ± .50  2.55 ± .61
 
   Periosteal BFR/BS 1.79 ± .56 2.37 ± .78 2.10 ± .49 2.55 ± .61 
   Endosteal MS/BS 0.07 ± .08 0.71 ± .16* 0.32 ± .19
p=0.053
 0.91 ± .18* 
   Endosteal MAR 1.65 ± 1.2 0.92 ± .29 0.63 ±  .18 1.03 ± .45 
   Endosteal BFR/BS 0.08 ± .13 0.72 ± .33* 0.15 ± .15 0.96 ± .48* 
             
Total Endosteal             
   MS/BS 0.53 ± .17 0.86 ± .06* 0.69 ± .07
p=0.097
 0.89 ± .07* 
   MAR 1.92 ± .24 1.46 ± .31* 1.20 ± .24
#
 1.13 ± .37 
   BFR/BS 1.13 ± .12 1.25 ± .24
p=0.094
 0.83 ± .17
p=0.053
 0.99 ± .30 
Total Periosteal             
   MS/BS .43 ± .03 .64 ± .27 .71 ± .09
#
 .84 ± .11 
   MAR 2.23 ± .71 2.18 ± .43 2.34 ± .53 2.40 ± .62 
   BFR/BS .97 ± .31 1.49 ± .86 1.71 ± .61
#
 1.99 ± .49 
 
Table 4.3.  Regional Dynamic Histomorphometry.  Dynamic histomorphometry of femoral 
cortical bone.  Regional anterior-posterior femoral cortical dynamic histomorphometry analyses 
are shown on top, with traditional data from the entire periosteal and endosteal surface at the 
bottom.  MAR was treated as a missing value when no dual label was present.  Deviations from 
n=6-9 group size are noted here.  Periosteal Anterior MAR (WT Veh n=0, WT Scl-Ab n=3).  
Endosteal Posterior MAR (WT Veh n=2, Brtl/+ Veh n=5).  *p<0.05 Scl-Ab vs. Veh;   
#
p<0.05 
WT Veh vs. Brtl/+ Veh.   
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CHAPTER 5 
Tissue Level Mechanical Properties and Matrix Composition After Scl-Ab Treatment in  
Rapidly Growing and Adult Brtl/+ Mouse Models of OI 
 
Introduction 
The mechanical competence of bone is a product of geometry and its material properties 
and composition.  Osteogenesis imperfecta (OI), also known as “brittle bone disease,” is a 
genetic collagen-related disorder which causes fragile bones [1].  Increased fracture risk of OI is 
often a product of altered bone geometry and material.   
Sclerostin antibody (Scl-Ab) is a new anabolic therapy presently in clinical trials for post-
menopausal osteoporosis [2, 3].  Numerous studies in a variety of animal models have 
demonstrated the efficacy of Scl-Ab at stimulating bone formation and increasing bone mass [4–
7].  Recently, several studies have also described Scl-Ab as effective at increasing bone 
formation and strength in mouse models of OI, including those described in the previous three 
chapters [8–11]. 
However, the effect of Scl-Ab treatment on tissue level material properties and 
composition has not been well studied in any population.  Specifically, a single study described a 
nominal effect of Scl-Ab on back-scatter SEM and FTIR material composition outcomes in 
middle aged male rats and female monkeys [12].  The only study to examine the effect of Scl-Ab 
on tissue level mechanical properties, and in OI, is reported in Chapter 2 of this dissertation [8].  
However, due to technique limitations, this analysis was performed in dehydrated samples.  In 
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addition, these animals were not rapidly growing and this is not an ideal model for pediatric OI.  
While tissue level material properties of Scl-Ab treated bone were studied for the first time in 
Chapter 2, material composition of bone formed under the influence of Scl-Ab has not yet been 
studied in OI.   
 Therefore, the purpose of this study was to examine the material composition by Raman 
spectroscopy, and hydrated tissue level mechanical properties by nanoindentation, of rapidly 
growing 3 wk and adult 6 mo Brtl/+ mice treated with Scl-Ab [13].  Utilizing fluorescent labels 
given throughout the course of a 5 wk Scl-Ab treatment regimen, we were able to rigorously 
control for tissue age.  We hypothesize that Scl-Ab will not have large effects on material 
property and composition, but tissue age and animal age will significantly influence these 
outcomes. 
  
Materials and Methods 
Animals 
Wildtype (WT) and Brtl/+ [13] mice are maintained on a mixed background of 
Sv129/CD-1/C57BL/6S, and all Brtl/+ animals were the product of breeding male heterozygous 
Brtl/+ with female WT.  3 week and 6 month old male WT and Brtl/+ mice were randomly 
assigned to Scl-Ab (Scl-Ab VI, Amgen, Thousand Oaks, CA) treatment or vehicle injection 
(PBS).  Sclerostin antibody was injected subcutaneously at 25 mg/kg, two times per week, for 
five weeks.  Calcein (30mg/kg, i.p. injection) was injected at the start of experiment (3 weeks 
animal age, 5 weeks before euthanasia), after 2 weeks of treatment (5 weeks animal age, 3 weeks 
before euthanasia), and after 4 weeks of treatment (7 weeks animals age, 1 week before 
euthanasia).  A final alizarin label (30mg/kg, i.p. injection) was given 1 day before euthanasia 
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(7weeks + 6 days of animal age).  The multiple fluorescent labels were used to visualize the 
growth pattern during the entire course of therapy.  Body weights were recorded with each 
injection.  Right femurs were harvested and stored at -20˚C in lactated ringers solution (LRS) 
soaked gauze until testing or further specimen preparation. All protocols and procedures 
involving animals were approved by the University of Michigan’s Committee on Use and Care 
of Animals. 
Two distinct cohorts of animals were used for this study.  Nanoindentation data was 
performed on the same animals described in Chapters 3 and 4, on the same femurs used for 
dynamic histomorphometry.  These samples underwent ~2-4 freeze cycles in the course of 
harvesting and specimen preparation, but this was not rigorously controlled for.  Nanoindentation 
group sizes are n=7-9/group before accounting for testing errors. 
All Raman spectroscopy tests were performed on a new cohort of animals (both 3 wk and 
6 mo) that were treated in an identical manner as described above.  This additional cohort of 
animals was added to control for, and limit, the number of freeze/thaw cycles which have the 
potential to confound Raman spectroscopy results [14].  All Raman spectroscopy data was 
collected on femora that had one freeze/thaw cycle prior to imaging.  All Raman Spectroscopy 
data was n=5-7/group. 
 
Nanoindentation Specimen Preparation 
Right femora were thawed, encased in a quick setting (~30min) epoxy (Kold Mount, 
Vernon-Benshoff, Albany, NY) without dehydration, and cut transversely at the mid-diaphysis 
with a low-speed saw (IsoMet, Beuhler, Lake Bluff, IL). The distal section of tissue was polished 
using progressive grades of silicon carbide abrasive paper (1200, 2400, and 4000 grit) under 
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water irrigation for two minutes at each grade.  Each specimen was polished to a plane just distal 
to the third trochanter, identical to that performed by dynamic histomorphometry, and similar to 
a plane included in our cortical microCT and mechanical 4pt testing data reported in Chapters 3 
and 4.  To further decrease surface roughness for nanoindentation, the encased specimens were 
polished on a felt pad for 5 minutes with a ¼ µm diamond suspension (Streurs Inc., Cleveland, 
OH).  Specimens were then ultrasonically cleansed in a water bath for 10 minutes to remove 
surface debris, and glued to a glass slide specimen plate for nanoindentation testing in a custom-
made hydration chamber.   
 
Nanoindentation 
A custom 950 TI TriboIndenter (Hysitron, Minneapolis, MN) instrumented with a 
fluorescent light-source and FITC filter allowed for simultaneous visualization of calcein 
labeling in specimens and accurate positioning of indents to locations matched for tissue age and 
treatment status with 0.5 µm spatial resolution. Five (rapidly growing) or six (adult) regions of 
interest were mechanically tested in the posterior aspect of the femoral cross section (Fig 5.2):  
the mid-cortex (defined as midway between the first calcein label on the periosteal and endosteal 
surfaces, if any), 15 µm endosteal to (“inside”) the first 5 wk old label, along the first calcein 
label on 5 wk old bone, along the second calcein label on 3 wk old bone, along the third calcein 
label on 1 wk old bone, and along the final alizarin label on 1 day old bone.  As our fluorescent 
nanoindenter only has a FITC filter and adding a second filter is not possible, the outer alizarin 
label positions were identified by looking at dynamic histomorphometry images taken of these 
same bones (Chapters 3 and 4) and measuring the distance from the 1 wk old calcein label.   The 
mid-cortex and 15 um endosteal to the 5 wk label positions were nearly identical locations in 
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rapidly growing 3 week animals.  As such, nanoindentation values were only collected at one 
location and characterized as “15 um inside 5wk” label in all analysis.   As Veh treated 6 mo old 
animals grow much slower than 3 wk old animals, it was not always possible to delineate the 
outer 1 wk and 1 day old labels in adult 6 mo mice as they appeared in the same location.  
Moreover, nanoindentation requires spacing between indents to not indent on the tissue 
deformed by a previous indent.  Therefore, in these instances, data was only collected in one 
location, and it was treated as a tissue age of 1 wk. 
Indentation consisted of a 10 µN pre-load, with a diamond Berkovich indenter tip into 
samples, followed by loading the sample at 300 µN/s, hold at a maximal load of 3,000 µN for 10 
s, and unloading at 300µN/s.  The indentation modulus E was calculated from the load-
displacement curves using the standard Oliver-Pharr method [15]. Eight indents, 10 µm apart, 
were made along each fluorescent label and region of interest, with values averaged for each site 
and mouse.   
 
Raman Spectroscopy 
 Raman measurements were performed with a custom microscope outfitted for Raman 
spectroscopy as previously described [16]. Briefly, Raman spectra were collected by directing a 
785-nm stabilized diode laser (Invictus, Kaiser Optical Systems, Inc., Ann Arbor, Michigan) 
through a Nikon E600 microscope (Nikon Instruments Inc., Melville, New York) with a 
40x/0.90 NA objective (S Fluor, Nikon Instruments, Inc., Melville, New York) operated in epi-
illumination and collection. Collected light from the sample was passed through an imaging 
spectrograph with a 50-μm slit (Holospec f/1.8i, Kaiser Optical Systems, Inc., Ann Arbor MI) 
and detected with a deep depletion, back-illuminated CCD camera (DU 401-BR-DD, Andor 
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Technologies, South Windsor, Connecticut). Estimated spectral resolution is ~8 cm
-1
. After data 
preprocessing, the estimated imaging spot size is 2.3 by 69.1 μm. 
For each specimen, periosteal bone was mapped in a 9 by 4 grid from the map origin. The 
map origin was defined as the upper left corner of a relatively flat and uniform region of the 
bone. The 9 measurement rows were determined by the fluorescent labels. The 4 measurement 
columns spanned were equally spaced 75 μm apart starting from the origin.  The 9 measurement 
locations, as guided by the fluorescent labels, were the midcortex, 15 μm endosteal to the 5 week 
old bone label, atop the 5 weeks old bone label, halfway between the labels marking 5 and 3 
weeks old bone, atop the 3 weeks old bone label, halfway between the labels marking 3 weeks 
and 1 week old bone, atop the 1 week old bone label, halfway between the 1 week and 1 day old 
bone label, and atop the 1 day old bone label (Fig. 5.1, 5.2). At each location, a spectrum was 
collected in 120 s with ~ 45 mW laser power. Custom-built Matlab (The Mathworks, Inc., 
Natick, MA) software was employed for data processing. The processing routine included 
cosmic spike correction, dark subtraction, correction for spectrograph slit curvature, calibration 
for wavelength-dependent changes in the CCD’s quantum efficiency, and wavenumber 
calibration.  
Raman spectroscopic parameters were computed with locally written scripts to assess 
changes in the mineral and matrix components of the cortical bone.   Carbonate content was 
analyzed by assessing the carbonate to phosphate ratio (1070 cm
-1
/959 cm
-1
).  The mineral to 
matrix ratio was assessed, and defined as the intensity of the phosphate 1 band at 959 cm
-1
 
divided by the maximum intensity of the proline and hydroxyproline bands between 850 and 880 
cm
-1
 . 
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Statistics 
Comparisons between tissue ages were made with a two-factor general linear model with 
repeated measures.  Specifically, within each animal age, genotype (WT and Brtl/+) and 
treatment (Veh and Scl-Ab) were between-subjects factors, and tissue age identified as a within-
subjects factor.  All pairwise tissue age comparisons were performed with a conservative 
Bonferroni correction to a reference point of 5 weeks of tissue age  A tissue age of 5 weeks was 
chosen as the reference, instead of mid-cortex, because this allowed us to control for tissue age 
across two animals ages and directly contrast findings between rapidly growing and adult 
animals.  These data are shown in Fig 5.3, 5.5 and 5.7. 
To assess the overall effect of genotype, and treatment, within a specific tissue age, a two 
factor multivariate model was performed with genotype (WT and Brtl/+) and treatment (Veh and 
Scl-Ab) as the between subjects factors that were analyzed at each tissue age.  These data are 
shown in Fig 5.4, 5.6, and 5.8. 
To assess the overall effect of animal age on material property and composition when 
controlling for tissue age, a three factor multivariate model was employed, with animal age 
(rapidly growing 3 wk and adult 6 mo), genotype (WT and Brtl/+), and treatment (Veh and Scl-
Ab) as the between subjects factors that were analyzed for each outcome at all tissue ages.  The 
data for animal age is shown in Fig. 5.10. 
p<0.05 was considered significant in all cases.  Mean ± standard deviation is shown unless 
otherwise noted. 
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Results  
Treatment Effect:  Scl-Ab Decreases the Carbonate to Phosphate Ratio, Increases the Mineral to 
Matrix Ratio, and Does not Affect the Elastic Modulus 
 In rapidly growing animals, Scl-Ab significantly decreased the carbonate to phosphate 
ratio at all tissue ages with the exception of 1 Day old bone (Fig 5.4).   In adult 6 mo animals, 
Scl-Ab significantly reduced the carbonate to phosphate ratio only at newer tissue ages of 1 
Week, 4 Days, and 1 Day (Fig 5.4).  This led to a different pattern of carbonate to phosphate 
ratios across the fluorescent labeled region (5 Week to 1 Day) of bone in 6 mo Scl-Ab treated 
WT and Brtl/+ when compared to Veh controls (Fig 5.3).  Specifically, newer tissue ages of 2 
Weeks, 1 Week, 4 Days, and 1 Day had significantly lower carbonate to phosphate ratios than 5 
week values in Scl-Ab treated specimens.  Correspondingly, no differences were noted below 5 
week old tissue age in Veh controls. 
 In 6 mo old specimens, Scl-Ab significantly increased the Mineral to Matrix ratio at 
Tissue ages of 4 wks, 3 wks, and 2 wks on the periosteal posterior surface of the diaphyseal 
femur (Fig. 5.6).  In rapidly growing (3 wk) animals, Scl-Ab only increased the mineral to matrix 
ratio at a location 15um inside the 5week label.  
The elastic modulus measured by nanoindentation was not significantly affected by Scl-
Ab at any tissue age in rapidly growing (3 wk) or adult (6 mo) animals (Fig 5.8).  
 
Genotype Effect:  Brtl/+ Has Increased Mineral to Matrix and Elastic Modulus at Some Tissue 
and Animals Ages, and Transient Decreases in Carbonate to Phosphate 
Overall phenotypic changes in the carbonate to phosphate ratio due to mouse genotype 
were small and few.  In rapidly growing 3 wk Brtl/+ mice, significantly lower carbonate to 
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phosphate was observed at the newest tissue age of 1 day, and 4 week old bone relative to WT 
(Fig 5.4).  No differences in the carbonate to phosphate ratio were observed between Brtl/+ and 
WT in adult 6 mo old animals at any tissue age, despite consistent but non-significant reductions 
in the mean. 
Increases in Brtl/+ mineral to matrix ratio were observed in both rapidly growing and 
adult animals.  Specifically, in 6 mo adult animals, increased mineral to matrix ratios were 
observed at tissue ages of 3 weeks, 4 weeks, 5 weeks, and 15um inside the 5week label (Fig 5.6).  
In rapidly growing 3 weeks animals, significantly increased mineral to matrix ratio was observed 
at 4 weeks of age, 15um inside the 5 week label, and at Mid-Cortex.  
No changes in elastic modulus were observed in rapidly growing 3 week old animals (Fig 
5.8).  Brtl/+ mid-cortex values were significantly greater than WT in adult 6 mo old animals, but 
no changes were observed at other tissue ages (Fig 5.8). 
 
Tissue Age Effect:  Elastic Modulus and Material Composition Continue to Increase with Tissue 
Age in Adult Mice, But Plateau in the Rapidly Growing Mice 
 In rapidly growing 3 wk and adult 6 mo animals, the carbonate to phosphate ratio was not 
changed at tissue ages of 5weeks or less in Veh treated animals. In 6 mo old adult animals, mid-
cortex and tissue 15um inside the 5week label had a significantly greater carbonate to phosphate 
ratio relative to 5 week values in all groups (Fig 5.3).  In rapidly growing animals, mid-cortex 
and tissue 15um inside the 5week label were not significantly different than mid-cortical 
controls. 
 In adult 6 mo old WT and Brtl/+, increasing tissue age is associated with increasing 
mineral to matrix ratio, with the highest levels seen at mid-cortex (Fig 5.5). In rapidly growing 
103 
 
animals, the mineral to matrix ratio increased rapidly until peak values were achieved at ~3weeks 
of tissue age.  At tissue ages greater than 3 weeks in rapidly growing animals, increasing tissue 
age correlated with decreased mineral to matrix ratios (Fig 5.5, 5.9).  The mean slope of the 
mineral to matrix ratio from 3 weeks of tissue age to 5 weeks of tissue age in all rapidly growing 
animals is negative (-1.06/day) and significantly less than the positive slope observed in adult  
6 mo animals over this same time period (0.098/day) (Fig 5.9).  
 The pattern of elastic modulus was similar to that observed in the mineral to matrix ratio.  
Specifically, in adult 6 mo animals, increasing tissue age was associated with increasing elastic 
modulus, and the highest levels were observed at mid-cortex (Fig 5.7).  By contrast, in rapidly 
growing animals, the elastic modulus reached peak values at ~3weeks of tissue age, and further 
increases were not observed with increasing tissue age.  The mean slope of the elastic modulus 
from 3 weeks of tissue age to 5 weeks of tissue age in rapidly growing animals is negative  
(-0.035GPa/Day), and significantly less than the positive slope observed in adult 6 mo animals 
(0.148GPa/Day) over this same time period (Fig 5.9). 
 
The Age of the Animal at Which a Tissue was Formed, Independent of the Age of the Tissue, 
Influences Material Composition and Elastic Modulus 
 The graphs in Figure 5.10 show the estimated marginal means across all groups within an 
animal age.  The estimated marginal means account for treatment and genotype effects, and are 
not the simple average of all values from a certain animals age.  They serve to make clear the 
differences between animal age that are (sometimes) visually apparent in Figures 5.3, 5.5, and 
5.7.  
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 Adult 6 mo animals had a significantly greater carbonate to phosphate ratio at all Tissue 
Ages (1 Day through Mid-Cortex) when compared to rapidly growing animals (Fig 5.10). 
 The differences in mineral to matrix ratio between adult 6 mo animals and rapidly 
growing 3 week animals depend on tissue age (Fig 5.10).  Between tissue ages of 4 weeks and 1 
week, rapidly growing animals had a greater mineral to matrix ratio than adult 6 mo animals.  At 
the newest, and oldest tissue ages, 6 mo animals had a greater mineral to matrix ratio.  
Specifically, adult 6 mo animals had a greater mineral to matrix ratio than rapidly growing 
3week animals at a tissue age of 1 day, and at Mid-Cortex and 15um inside the 5 week label. 
 Elastic modulus in 6 mo old animals was significantly greater than rapidly growing 3 
week animals at tissue ages of 3 weeks and 5 weeks, and at a location 15um inside the 5 week 
label (Fig 5.10).  
 
Discussion 
 While we have previously demonstrated that Scl-Ab can increase bone mass and strength 
in a mouse model of OI, this study represents the first investigation into the effect of Scl-Ab on 
the material composition of OI tissue. Although overall effects of Scl-Ab was often similar 
between WT and Brtl/+, the data did demonstrate that Scl-Ab has an effect on material 
composition.  However, despite these effects on composition, no significant effect on elastic 
modulus was observed.  Collectively, this study adds to an emerging, but extremely limited, set 
of data describing the effect of Scl-Ab on material property and composition.    
Before discussing the data in detail, two brief comments on nomenclature as it relates to 
interpretation of the “tissue age” data are merited.  First, numerous references are made to bone 
of a certain tissue age; for example, “at a tissue age of 3 weeks”.  Tissue age, however, can be a 
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misleading term in this application.  A more precise definition is, “A region of bone that had a 
fluorescent calcein label bind to it 3 weeks before the animal was euthanized”.  With the 
understanding that calcein rapidly binds to mineral, this should be interpreted as “a region of 
bone that just started to mineralize 3 weeks before the animal was euthanized”.  Mineralization 
lag time has been ignored.  This may be convenient, and even ideal.  However, one should be 
cognizant of this. 
Second, fluorescent label that bound to a tissue 5 weeks ago may not be indicative of the 
fact that all tissue in a particular region has been mineralizing for 5 weeks.  For example, in 
rapidly growing animals the “5 week old” tissue age on posterior surface is anatomically located 
near the middle of the cortex, and characterized by porous woven looking bone (Fig 5.2, 5.11).  
It is possible that some level of apposition continues in these pores after the initial woven bone is 
laid down, and this may even be modulated by treatment.  It should be noted that tissue ages 3 
weeks or newer in rapidly growing animals were always lamellar in appearance.  In adult 6 
month old animals, all bone throughout the five week treatment period was lamellar in nature.  
Finally, it is important to note that tissue ages at mid-cortex and 15um inside the 5 wk label in 
adult animals are almost certainly greater than in rapidly growing 3 wk mice, and should be 
interpreted as such.   
Interestingly, the pattern of material composition and elastic modulus with tissue age is 
different between rapidly growing 3 wk, and adult 6 mo, animals.  In both adult and rapidly 
growing animals we observed a rapid increase in the mineral to matrix ratio from tissue ages of 1 
day through 3 weeks.  However, after 3 weeks of age, the pattern diverged.  Adult animals 
continued to increase the mineral to matrix ratio and elastic modulus from 3 weeks of tissue age 
through 5 weeks of tissue age (Fig 5.9).  Conversely, we observed decreasing mineral to matrix 
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ratio and elastic modulus in rapidly growing animals from 3 weeks of tissue age to 5 weeks of 
tissue age.  These findings may be related to the woven nature of the bone present beginning 
between 3 and 5 weeks of tissue age (Fig 5.2, 5.11).   
While the pattern of the mineral to matrix ratio and elastic modulus across tissue age 
correlated with one another at different animals ages (Fig 5.9), a positive correlation between 
these two variables was not always observed.  For example, the absolute value of the mineral to 
matrix ratio was greater in rapidly growing 3 wk mice than adult 6 mo animals, but rapidly 
growing 3 wk animals had a lower elastic modulus at some tissue ages (Fig. 5.10).  Although the 
mineral to matrix ratio often positively correlates with the elastic modulus, numerous factors can 
modulate this relationship.  In support of this notion, less than half of the variation in tissue level 
elastic modulus has been reported to be explained by tissue mineralization [17].  Some of these 
factors are explicitly related to alterations within the mineral component, and would not be 
captured by the mineral to matrix ratio which measures the relative amount of mineral.  For 
example, a recent study showed that in regenerate bone, the orientation of apatite crystals, rather 
than BMD, correlated with Young’s modulus [18].  It is possible that alterations apatite crystal 
orientation in regions of woven bone could account for differences in the correlation between 
elastic modulus and mineral to matrix ratio.  In addition, mineral crystallinity describes a quality 
of the mineral not captured in the mineral to matrix ratio, and may independently modulate the 
relationship between mineralization and elastic modulus [19–21].   
Many other factors describing material composition can modulate the elastic modulus.   
In addition to outcomes describing specific qualities of the mineral, additional factors relating to 
the organic component of bone can also affect the elastic modulus.  The organic component of 
bone is 90% Type I collagen, but extracellular matrix proteins which comprise the remaining 
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10% can also have a significant effect on material properties.  Among many examples, both 
osteocalcin and TGF-  have been shown to affect the tissue level elastic modulus, in addition to 
other mechanical parameters [22, 23].  In addition, collagen cross-linking is another organic 
factor has been shown to influence the elastic modulus of bone [24, 25].  The relationships 
between composition and mechanical property are complex and span interactions at multiple 
hierarchical levels.  Moreover, the relationship between mechanical property and material 
composition have been shown to vary with animal age [25, 26].   
In this study, the carbonate to phosphate ratio was highest at mid-cortex of adult 6 mo 
animals (Fig 5.3).  The lack of difference at mid cortex in rapidly growing 3 week animals is 
likely attributable to the relatively small difference in tissue age between mid-cortex and 5 week 
old bone, when compared to adult 6 mo animals.  Unique from mineral to matrix ratio and elastic 
modulus, tissue age and the presence of woven bone do not appear to affect carbonate to 
phosphate ratios in rapidly growing animals.  Moreover, carbonate to phosphate does not vary 
across the fluorescently labeled 5 weeks of bone in Veh treated adult 6 mo WT and Brtl/+. 
We observed that Scl-Ab reduced the carbonate to phosphate ratio in both rapidly 
growing and adult mice, although the effect was different within each animal age (Fig 5.4).  In 
adult mice, reduced carbonate to phosphate was only observed at very young tissue ages of 1 
week or less.  Conversely, in rapidly growing mice, a reduced carbonate to phosphate ratio was 
observed at nearly all tissue ages.  Effects of bone material composition by Scl-Ab have only 
recently begun to be examined, with a single report suggesting an opposite effect of reduced 
carbonate substitution with Scl-Ab treatment [12].  The cited study was performed in the 
trabecular bone of 4-5 year old cynomolgus monkeys, with different specimen preparation, and 
by FTIR; all factors which may be related to our differential result.   
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In our study, Scl-Ab transiently increased the mineral to matrix ratio at some tissue ages 
and animal ages.  Specifically, in rapidly growing 3 week animals, Scl-Ab significantly increased 
the mineral to matrix ratio only at a location 15um inside the 5week old label.  The isolated 
nature of this effect suggests it should be interpreted with caution.  In contrast, in adult 6 mo 
animals, a transient pattern of increased mineral to matrix with Scl-Ab was observed at 2 weeks, 
3 weeks and 4 weeks of tissue age with Scl-Ab.  This finding correlates with data at the 
intracortical compartment of  4-5 year old cynomolgus monkeys [12].  In this study, the elastic 
modulus data did not reveal a significant effect of Scl-Ab. 
The finding of small but significant increases in mineral to matrix in Brtl/+ vs WT 
animals (Fig 5.6) is in agreement many studies that have consistently found increased 
mineralization and TMD in this OI mouse model [27, 28].  Unique from these prior studies is 
that the data in this study controls for tissue age, and suggests that differences in mineral to 
matrix do not present at tissue ages <3weeks in adult mice.  Similar findings were observed in 
rapidly growing animals and significant differences were not observed at tissue ages <4 weeks.  
While it may be tempting to conclude that Brtl/+ and WT mineral to matrix levels start out at 
identical levels, and only diverge with secondary mineralization, a quick inspection of the data 
reveals non-significant trends that are present in young tissue.  These should not be conveniently 
dismissed.  The elastic modulus was significantly greater at mid-cortex of adult 6 mo Brtl/+ 
animals, but no phenotypic differences were observed in rapidly growing animals.   
Perhaps most interesting is the data which suggests that at two different animal ages, 
bone of an equivalent tissue age can be of a different material property and composition.  For 
example, our data show that even when controlling for tissue age, increased carbonate to 
phosphate ratio is observed at all tissue ages.  Thus, it is not simply tissue age which accounts for 
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differences in material composition in old vs young animals.  Rather, the age of the animal at 
which a tissue was initially formed also accounts for some of its composition.  Differences in the 
mineral to matrix ratio and elastic modulus were also observed between animal ages when 
controlling for tissue age.   While several studies have utilized fluorescent labeling to look at the 
effect of tissue age within a single animal age [29, 30], this technique has not been utilized 
across different animal ages.  However, studies have touched on such an interaction by 
examining numerous tissue ages [19, 26], or inferring tissue age by osteonal morphology [31]. 
 There are several important limitations to this study.  First, raman spectroscopy and 
nanoindentation were carried out in separate animals.  While this prevented direct correlations 
from data taken at identical locations, similar trends observed in different animals provide 
independent confirmation of main effects.  Second, our data is limited to cortical bone of the 
posterior femur in a mouse model.  What happens at one skeletal site and species may not be true 
in another.  Additionally, as nanoindentation primarily quantifies pre-yield mechanical effects, 
future studies should examine post-yield effects at the tissue level.  Band-fitting of raman 
spectroscopy data is currently underway to assess changes in cross-linking.  Finally, as OI is a 
disease of many mutations, the results from one OI type may not extend to another.  Therefore, 
these data should be tested in other dominant and recessive OI types that feature unique 
mutations and phenotypes. 
 In conclusion, our data suggest that Scl-Ab affects material composition, decreasing the 
carbonate to phosphate ratio, while imparting transient increases in mineral to matrix.  In 
addition, by controlling for tissue age across two animals ages, we have directly shown that age 
of an animal at which bone is formed can influence tissue composition and mechanical 
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properties.  For the material properties and compositional parameters we analyzed in this study, 
the data does not suggest that there are unique concerns of Scl-Ab use in a Brtl/+ model of OI. 
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Figure 5.1:  Experimental Design and Fluorescent Label Timing.  Experimental design and 
calcein labeling scheme for these experiments is shown above, and is the same as that used in 
Chapters 3 and 4.  The final alizarin label was given 1 Day before euthanasia. 
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Figure 5.2:  Raman Spectroscopy and Nanoindentation Data Collection Locations.  All data collected at mid-diaphyseal femur of 
rapidly growing 3wk-8wk and adult 6mo-6mo+5wk animals.  Calcein and alizarin labels were given as shown in Fig 5.1.  
Nanoindentation was not performed between labels due to resolution issues, or collected at mid-cortex in rapidly growing animals 
because it was nearly identical in location to the “15um inside 5wk” label location.  In some adult 6mo Veh specimens, the 1wk and 1 
Day labels were almost on top of each other.  As indents for nanoindentation can not be placed on top of one another, in some cases, 
data was only collected for 1 week old tissue.  The 6 month animal shown is treated with Scl-Ab and has much greater separation 
between labels than that typical of adult 6mo Veh mice. 
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Figure 5.3:  Carbonate to Phosphate Ratio.  Carbonate to Phosphate ratio at nine tissue ages on the periosteal posterior surface of the 
mid-diaphyseal femur.  All differences from a 5 week tissue age (orange bars) are shown within each experimental group.  Lines 
indicate p<0.05, repeated measures pairwise comparison with Bonferonni correction.  All data is mean±stdev.  
 
 
 
 
 
114 
 
 
Figure 5.4:  Carbonate to Phosphate Ratio (grouped by Tissue Age).  Carbonate to Phosphate ratio at nine tissue ages on the periosteal 
posterior surface of the mid-diaphyseal femur.  This is the same data shown in figure 5.3, but formatted to reveal differences of 
treatment and genotype within tissue age.  P-values listed represent the result of a two-factor analysis and show the overall effect of 
genotype and treatment at each tissue age.  All data is mean±stdev.  
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Figure 5.5:  Mineral to Matrix Ratio.  Mineral to Matrix ratio at nine tissue ages on the periosteal posterior surface of the mid-
diaphyseal femur.  All differences from a 5 week tissue age are shown within each experimental group.  Bars indicate p<0.05, 
repeated measures pairwise comparison with Bonferonni correction.  All data is mean±stdev.  
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Figure 5.6:  Mineral to Matrix Ratio (grouped by Tissue Age).  Mineral to Matrix ratio at nine tissue ages on the periosteal posterior 
surface of the mid-diaphyseal femur.  This is the same data shown in Figure 5.5, but formatted to reveal differences of treatment and 
genotype within tissue age.  P-values listed represent the result of a two-factor analysis and show the overall effect of genotype and 
treatment at each tissue age. All data is mean±stdev.  
 
 
117 
 
 
Figure 5.7:  Elastic Modulus.  Elastic Modulus as measured by nanoindentation at nine tissue ages on the periosteal posterior surface 
of the mid-diaphyseal femur.  All differences from a 5 week tissue age are shown within each experimental group.  Bars indicate 
p<0.05, repeated measures pairwise comparison with Bonferonni correction.  All data is mean±stdev.  
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Figure 5.8:  Elastic Modulus (grouped by Tissue Age).  Elastic Modulus as measured by nanoindentation at five or six tissue ages on 
the periosteal posterior surface of the mid-diaphyseal femur.  This is the same data shown in Figure 5.7, but formatted to reveal 
differences of treatment and genotype within tissue age.  P-values listed represent the result of a two-factor analysis and show the 
overall effect of genotype and treatment at each tissue age. All data is mean±stdev.  
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Figure 5.9:  Mineral to Matrix and Elastic Modulus Slopes (Grouped by Animal Age).  These plots are of the same data shown in 
Figures 5.3, and 5.7, but displayed on top of one another in order to aid visualization of similar patterns between the two tissue ages.  
For mineral to matrix, and elastic modulus, the average slope of all specimens from 3 weeks of  tissue age, to 5 weeks of tissue age 
was quantified for rapidly growing 3 week and adult 6mo animals.  The sign of the slope value describes correlation with increasing 
tissue age, and increasing tissue age is shown moving in the left direction on the graph – the reason for the apparent contradiction.  
Data shown are means, but stdev is not plotted here 
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Figure 5.10:  Effect of Animal Age on Material Composition and Property Independent of Tissue Age.  Differences between 
Carbonate to Phosphate, Mineral to Matrix, and Elastic Modulus exist between animal ages, even when controlling for tissue age (i.e., 
tissue ages 5 weeks or less).  These differences are apparent in Figures 5.3, 5.5 and 5.7, but can be hard to visualize.  Here, we plot the 
estimated marginal means for each variable across genotype and treatment, and patterns were similar between tissue age.  Significant 
differences from a three-factor anova (Animal Age p-values displayed on graph) suggest that material properties and composition are 
influenced by animal age, independent of tissue age.  All data is mean±stderr. 
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Figure 5.11:  Presence of Woven Bone in Rapidly Growing vs Adult Mice.  WL Images show presence of woven bone on the 
posterior mid-diaphyseal femur of rapidly growing animals (8wk at euthanasia) used in this study.  This is also seen in the fluorescent 
image shown in Fig 5.2  No woven bone is visible in the adult 6mo+5wk animals.
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CHAPTER 6 
Discussion and Conclusion 
 
 Much of the data has already been discussed at length in the respective discussion 
sections for each chapter.  This will not be repeated here.  However, some discussion points that 
outline technical considerations, integrate broader concepts, and offer future perspective, are 
included below. 
 
Interpretation of Dynamic Histomorphometry Data 
 Chapters 3 and 4 of this thesis included the presentation of regional dynamic 
histomorphometry data.  Traditionally, cortical dynamic histomorphometry data is presented as 
the average value over the entire periosteal or endocortical surface.  Discussed below, are the 
reasons and conditions to consider deviating from this standard. 
 There is a fundamental difference between amplifying sites of existing bone formation, 
and stimulating bone formation at sites that would otherwise be quiescent or resorbing.  When 
bone formation is stimulated at an unnatural location by an intervention, combining this data 
with regions that would normally have bone formation can bias the result. 
Mineral Apposition Rate, or MAR, quantifies the average distance between fluorescent 
labels (e.g. calcein) given when a mouse was alive.  The generally accepted interpretation of 
MAR is that it indicates osteoblast activity.  As specifically put by a recent consortium of experts 
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in skeletal biology and histomorphometry assembled by the American Society for Bone and 
Mineral Research, “… apposition rate represents in some sense the activity of a team of 
osteoblasts.” [1]  The common interpretation is that if MAR increases, osteoblast activity 
increased; and if MAR decreases, this indicates that osteoblast activity decreased. 
However, when new bone formation is stimulated in areas that were otherwise quiescent 
or resorptive, the relationship between MAR and osteoblast activity can become misleading.  
Consider the example shown in Fig 6.1.  If we assume that MAR is normally 1 on the periosteal 
surface of the top half of the bone, and no labeling is present on the bottom half of the bone, the 
average MAR is 1.  Now, let us assume that an anabolic intervention was taken that amplified 
bone formation on the existing top half of the bone (from 1 to 1.5), and stimulated bone 
formation to occur (from nothing to 0.5) on the bottom half.  The average MAR in this case 
would also be 1! (the average of 1.5 on the top half, and 0.5 on the bottom)  Thus, even though 
the anabolic intervention increased MAR at every skeletal location by 0.5, the average MAR did 
not change, and remained at 1.  Therefore, a typical conclusion of this data would be that the 
intervention did not alter osteoblast activity because the average MAR did not change, even 
though the osteoblast activity at every skeletal location was increased.  This does not make 
sense. 
The second example given in Fig. 6.2 is similar to above, and serves to illustrate the 
potentially absurd.  Without walking through the example again, we can see that a scenario is 
possible in which MAR is increased at every skeletal location, but the average MAR decreases.   
The regional analysis presented in Chapters 3 and 4 serves two purposes.  First, it 
separates dynamic histomorphometry data by anatomic location.  Second, as the pattern of bone 
formation is strongly conserved with anatomic location, it allowed us to separately analyze 
127 
 
regions of bone that were already forming bone, and regions that were largely quiescent or 
resorbing.  However, a defined anatomical pattern of bone formation may not be present in all 
instances, yet an investigator may still wish to separately analyze regions with pre-existing bone 
formation.  In such situations, one could administer a fluorescent label several days prior to the 
intervention, which would label all sites that were forming bone before the start of the 
experiment.  These regions could then be separately analyzed. 
For many studies, such a detailed analysis may be unwarranted and not provide additional 
insight.  However, in any scenario where an intervention or treatment alters mineralizing surface, 
and/or bone modeling, such an analysis method may clarify the data and should be considered.  
Two such examples are sclerostin antibody treatment as discussed in this dissertation, and 
mechanical loading studies, both of which stimulate bone formation at new skeletal locations.  
With the continuing emergence of treatments and skeletal interventions which stimulate new 
bone formation, consideration of this effect will become increasingly relevant.   
 
Relationship of Sclerostin Expression to Anatomical Location 
The regional dynamic histomorphometry data described in chapters 3 and 4 reveal several 
patterns of bone formation around the femoral mid-diaphyseal cortex.  First, the data confirm 
that cortical drift is strong in rapidly growing animals, with bone formation on the periosteal 
posterior surface, and endosteal anterior surface.  Conversely, the opposing endosteal posterior 
and periosteal anterior surfaces were either quiescent or resorptive.  This general pattern of 
cortical drift is maintained in adult 6 mo animals, but the formation rates are much lower.  In 
addition, we observed that Scl-Ab was able to consistently stimulate bone formation on quiescent 
surfaces in adult animals, but the Scl-Ab response on these surfaces was inconsistent in rapidly 
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growing mice.  Among several possible factors, we speculated that sclerostin expression levels 
around the cortex may be correlated to these findings. 
Given that sclerostin is an inhibitor of bone formation via the canonical wnt pathway, we 
broadly hypothesized that there would be an inverse correlation between regional sclerostin 
expression and regional patterns of bone formation.  That is, regions of cortex characterized by 
high levels of bone formation would exhibit low sclerostin expression, and vice-a-versa.  If true, 
this could explain several of our findings.  For example, as rapidly growing animals have high 
levels of bone formation relative to adult 6 mo animals, we hypothesized that there would be 
relatively greater sclerostin expression near sites of bone formation in adult 6 mo animals, 
compared to rapidly growing mice.  By dynamic histomorphometry, we found that sites already 
high in bone formation in rapidly growing animals were not responsive to Scl-Ab, but sites of 
pre-existing bone formation in adult animals were able to significantly increase MAR with 
treatment.  One potential explanation for the lack of a Scl-Ab effect in rapidly growing animals 
is sufficiently low sclerostin expression resulting in no protein for the treatment to inhibit.  
 Preliminary studies to answer these questions and assess sclerostin expression patterns 
are underway.  Specifically, we have performed immunostaining for sclerostin on 8 week old 
(rapidly growing) and 6 mo old (adult) WT and Brtl/+ untreated animals, with n=5/group (Fig 
6.3).  Stained transverse sections were located at a femoral mid-diaphyseal cortex location on 
transverse sections, identical to those analyzed by dynamic histomorphometry in Chapters 3 and 
4. 
The data is not definitive at this point, but several initial conclusions can be reached and 
qualitative observations suggest future research directions.  First, and perhaps not surprisingly, 
sclerostin IF images do not suggest that regional sclerostin levels inversely correlate with local 
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bone formation rate in a consistent manner.  For example, while sclerostin expression does 
appear lower on the periosteal posterior surface of 6 mo animals (a site of relatively high bone 
bone formation) when compared to the endosteal posterior surface, sclerostin expression is also 
very low on the posterior endosteal surface of 8 wk old animals (a site of low bone formation) 
(Fig 6.3). Although such an inverse correlation does not readily explain our results, initial 
sclerostin expression data does suggest several consistent patterns, as well as directions for future 
study, which are outlined below. 
There was a large variation in canalicular expression of sclerostin across the cortex, and 
these relative differences were more apparent than differences in osteocytic expression (Fig 6.3).   
Moreover, the differences in canalicular expression appear separated by a region of woven bone.  
This is particularly true in 8 wk old animals.  For example, in the posterior region of the femur, 
canaliculuar sclerostin expression is consistently low on the endosteal side of the woven bone, 
and relatively high on the periosteal side of the woven bone(Fig 6.3).  Whether this is a result of 
altered sclerostin expression in these regions, or simply an altered canalicular network, remain to 
be determined.  While enumeration of sclerostin positive osteocytes is a standard outcome of 
such analysis [2], the data presented here suggest that canalicular levels should not be ignored; 
particularly when the amount of sclerostin reaching cells on the bone surface is of primary 
importance. 
Additionally, we observed localization of sclerostin expression in the periosteum in both 
rapidly growing and adult animals.  The accumulation of an inhibitor of bone formation at a site 
of bone progenitor cells is intriguing, particularly at an anatomic location with high bone 
formation rates. 
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Unique Considerations of Scl-Ab Use in a Rapidly Growing, Pediatric OI Patient 
 The use of Scl-Ab in an adult OI population will likely be similar to that of osteoporotic 
patients, for which it is presently in FDA trials [3, 4].  While there will may be differences in 
effectiveness between OI type, as has been observed with PTH [5], the application of a Scl-Ab 
treatment regimen should be straightforward.   
However, dosing regimen and use of Scl-Ab in a pediatric population will require several 
unique considerations.  These include potential side-effects of Scl-Ab use in a developing 
skeleton, sequential or co-treatment with a BP, and Scl-Ab dosing regimen as it relates to 
efficacy over a protracted time period.  
Patients with sclerosteosis have too much bone growth, and experience side effects.  As 
these side-effects are thought to manifest during development, there are concerns about the use 
of Scl-Ab in a developing skeleton.  In particular, patients with sclerosteosis can experience 
intracranial apposition resulting in impaction of the foramina, leading to death [6, 7]. In defense 
of Scl-Ab use in the developing skeleton, a reasonable argument observes that these side-effects 
are confined to patients with two non-functioning sclerostin genes.  Meanwhile, sclerosteosis 
“carriers” that have one functioning copy of the SOST gene have elevated bone mass, but do not 
suffer these deleterious side effects [8].  Treatment with an inhibiting antibody is likely 
analogous to a sclerosteosis “carrier”, and complete inhibition of sclerostin by Scl-Ab treatment 
is unlikely.  Regardless, application of sclerostin inhibiting antibodies to a growing skeleton 
should proceed with caution. 
 A growing body of literature suggests that the anabolic effect of Scl-Ab is temporary, and 
bone formation levels, or serum markers of bone formation, revert to pre-treatment levels despite 
continued injections.  This has been demonstrated in adult rats over the course of 12-26 weeks, 
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and in human clinical trials of post-menopausal women over the course of a year[4, 9].  The 
duration of an anabolic Scl-Ab effect in the context of a pediatric skeleton is unknown.  
Moreover, this question is likely impossible to answer in murine models – where the age at 
puberty is similar or greater than the time the time it takes for an anabolic Scl-Ab effect to 
subside.  Animal models which age slower are necessary to answer this question.  But assuming 
that the anabolic effect subsides with ~1 year of Scl-Ab therapy in a pediatric OI patient, what 
action should be taken?  A simple suggestion might be to halt Scl-Ab therapy for a period of time 
until it again becomes effective.  However, this may be undesirable in a pediatric patient with 
rapid linear growth, leaving significant regions of new bone without the benefit of therapy.  
Moreover, Scl-Ab cessation without anti-resorptive treatment, may lead to loss of Scl-Ab 
induced bone gains.  
Presently, bisphosphonates (BP) are commonly used to treat OI and are capable of 
increasing bone mass, particularly in the axial skeleton.  When designing an OI and Scl-Ab 
clinical trial, it may be viewed as unethical to deny BP and have a true placebo control group.  
Rather, a combination treatment Scl-Ab+BP treatment strategy not only assuages ethical 
concerns, but may prove the best for patient outcomes.  Combination, and sequential, treatment 
strategies are currently being explored in animal models of OI. 
  
Perspective:  Brtl/+ Scl-Ab Data as it Relates to OI Patient Outcomes 
The outcomes observed in this dissertation are impressive, consistent with other Scl-Ab 
studies.  Indeed, after a 5 week treatment period with Scl-Ab, we were able to increase bone 
mass in adult 6 mo Brtl/+ by over 20% in cortical bone, increase cortical ultimate load by 127%, 
and trabecular BV/TV by 119%.  In a rapidly growing 3 wk Brtl/+ model of Type IV OI, Scl-Ab 
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treatment “rescued” Brtl/+ femoral strength to a level not significantly different than WT Veh 
controls.  This does not imply that Scl-Ab will have the same effect in humans, and this “rescue” 
certainly does not imply that Scl-Ab represents a “cure” – even for the specific case of Type IV 
OI. 
Treatment data from mouse models are almost always more impressive than that 
observed in humans.  The bone cells upon which a treatment acts remain of roughly similar size 
between humans and mice, but the bones of a mouse are orders of magnitude smaller.  This 
makes it easy for bone treatments to induce large gains, on a percentage basis, in murine bone 
mass.  By definition, an identical cellular response between humans and mice will result in 
different whole bone changes on a percentage basis. 
In addition, the body mass differences between Brtl/+ and WT animals confound simple 
interpretation of the Brtl/+ whole bone phenotype.  For example, at 8 weeks of age (Chapter 4), 
Brtl/+ Veh mice have 23.8% reduced Yield Load and  38.4% less Ultimate Load than WT Veh 
animals.  However, Brtl/+ mice also have 22.4% less body mass than WT at 8 weeks of age.  
Moreover, with time, both Brtl/+ body mass and whole bone strength approach WT levels.  At 
~7 months of age, Brtl/+ mice described in Chapter 3 only have an 8.5% reduction in the mean 
Yield Load, and a 13.5% reduction in Ultimate Load relative to WT Veh.  Correspondingly, 
mean Brtl/+ body mass is only reduced 9.5% at ~7 months of age.  Thus, while Brtl/+ bones are 
certainly weaker, particularly at young animal ages, it is inaccurate to call them less functional 
without consideration of body weight differences.  Indeed, the Brtl/+ mouse does not suffer 
spontaneous fractures.  While some deficits in bone strength and material property still remain in 
Brtl vs WT after accounting for body mass, the differences are not as large as the whole bone 
strength data suggest.  However, the critical demonstration of these studies is not a “rescue” of 
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Brtl/+ whole bone strength to WT Veh levels by Scl-Ab.  Rather, is it that Scl-Ab was able to 
stimulate Brtl/+ bone formation and increase cortical bone mass, which led to increase bone 
strength despite retention of the collagen material defect. 
 The success of Scl-Ab in OI patients will be explicitly related to its ability to stimulate 
bone formation in human OI osteoblasts.  Moreover, the ability of Scl-Ab to stimulate modeling 
bone formation in the diaphysis of long bones, particularly on the periosteal surface, will be of 
critical importance towards improving patient outcomes relative to bisphosphonates.    Mild 
cases of OI, such as Type I, are more likely to benefit from Scl-Ab treatment as moderate 
increases in bone mass can represent a significant portion of the fracture risk.  Consider the 
severe cases of Type IV OI, or Type III, where patient presentation is severe with progressive 
limb deformity and bone that can radiologically appear like “popcorn”.  Even if Scl-Ab is able to 
stimulate bone formation in these patients, any functional benefit is likely small relative to the 
severity of OI in the patient.  More generally, it is unlikely that any therapy which acts by 
inhibiting osteoclasts, or increasing osteoblast activity, will ever eliminate OI fracture risk.  
Continued investigation into therapies which attempt to address the underlying cause of OI (e.g. 
gene therapy) are paramount to improving OI patient outcomes. 
 
Conclusion 
 Despite all of the above limitations, Scl-Ab does represent a new candidate therapy for 
OI.  The ability to stimulate bone formation in the Brtl/+ mouse model is encouraging, and 
mechanistically different from presently available treatment options.   Critical to the success of 
Scl-Ab in OI patients, will be the ability to stimulate bone formation at cortical sites, particularly 
at the periosteal surface, as was demonstrated in the Brtl/+ mouse. 
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Figure 6.1:  Illustration of Confounding Effect of Average MAR.  Figure shows the potential 
effect of stimulating bone formation at a previously queisecent site on the average mineral 
apposition rate (MAR).  Even though bone formation rate increased at every skeletal location, 
the average MAR did not change. 
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Figure 6.2:  Additional Illustration of Confounding Effect of Average MAR.  Figures shows the 
potential effect of stimulating bone formation at a previously queisecent site on the average 
mineral apposition rate (MAR).  Even though bone formation rate increased at every skeletal 
location, the average MAR decreased.   
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Figure 6.3:  Sclerostin Immunofluoresnce Staining at Femoral Mid-Cortex.  Images are taken 
from mid-diaphyseal femur in 8 wk and 6 mo WT animals.   
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